Major Pharmaceuticals Industry Financials, Performance and Ratios
-
Industry Score
46.9 /100
Rank 52 out of 131 Industries -
Advance/Decline
111/237
-
No. of Companies348
-
Avg. Market Cap12,745
-
Price to Earning Ratio10.01
-
Price to Earning Growth Ratio0.76
-
Price to Book Ratio31.37
-
Return on Equity53.94
-
Return on Capital Employed-
-
Return on Assets12.07
-
Dividend yield 1 year %0.83 %
-
Net Profit Growth Annual YoY %-0.44 %
-
Net Profit Growth Qtr YoY %-64.38 %
-
Net Profit Growth Qtr QoQ %-71.54 %
Show more
*All values are market cap weighted averages.
*All Financial parameters are in Million USD.
Major Pharmaceuticals Industry Market Breadth
- < -5%
- -2 to -5%
- 0 to -2%
- 0 to 2%
- 2 to 5%
- > 5%
Major Pharmaceuticals Peer comparison
Compare all stocks in Major Pharmaceuticals industry listed on stock exchanges
| Stock Name | 3M Price Chart | Market Cap | LTPLast Traded Price | Day High Low (%) | Week High Low (%) | Month High Low (%) | Qtr High Low(%) | 1 Year High low(%) | 3 Year High low(%) | 5 Year High low(%) | 10 Year High low(%) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| AbbVie |
|
394,144.4
|
223.0
|
L
 1.2%
H
219.6
224.0
|
L
 1.7%
H
216.7
226.9
|
L
 -2.9%
H
210.0
237.0
|
L
 -2.3%
H
210.0
239.3
|
L
 27.0%
H
164.4
244.8
|
L
 53.1%
H
131.0
244.8
|
L
 117.6%
H
101.9
244.8
|
L
 306.2%
H
51.6
244.8
|
| Adc Therapeutics SA |
|
447.2
|
3.6
|
L
 -4.0%
H
3.5
3.8
|
L
H
3.3
3.8
|
L
 3.1%
H
3.3
3.9
|
L
 -22.0%
H
2.9
4.7
|
L
 109.9%
H
1.1
4.8
|
L
 -26.6%
H
0.4
6.0
|
L
 -87.4%
H
0.4
32
|
L
H
0.4
56.6
|
| Amneal Pharma Inc (Class A) |
|
4,300.5
|
13.7
|
L
 -3.1%
H
13.6
14.0
|
L
 2.2%
H
13.3
15
|
L
 6.2%
H
12.3
15
|
L
 36.8%
H
10.1
15
|
L
 59.4%
H
6.7
15
|
L
 554.5%
H
1.2
15
|
L
 184.4%
H
1.2
15
|
L
 -63.5%
H
1.2
38.4
|
| Annovis Bio Inc |
|
71.6
|
2.7
|
L
 -3.9%
H
2.6
2.9
|
L
 -10.3%
H
2.6
3.1
|
L
 -22.0%
H
2.6
4.1
|
L
 29.8%
H
1.9
5.5
|
L
 -44.8%
H
1.1
5.5
|
L
 -84.3%
H
1.1
23.9
|
L
 -72.9%
H
1.1
132
|
L
H
1.1
132
|
| Bausch Health Companies Inc |
|
2,126.8
|
5.7
|
L
 2.7%
H
5.5
5.7
|
L
 -2.9%
H
5.5
5.9
|
L
 -17.9%
H
5.5
8
|
L
 -13.2%
H
5.5
8
|
L
 -23.1%
H
4.3
8.7
|
L
 -26.6%
H
4.0
11.5
|
L
 -77.5%
H
4.0
34.8
|
L
 -93.6%
H
4.0
101.4
|
| Bristol-Myers Squibb |
|
112,068.2
|
55.1
|
L
 1.4%
H
54.3
55.1
|
L
 0.7%
H
54.2
56.1
|
L
 1.6%
H
52.1
57.0
|
L
 20.7%
H
45.2
57.0
|
L
 -6.9%
H
42.5
63.3
|
L
 -23.6%
H
39.4
75.2
|
L
 -10.4%
H
39.4
81.4
|
L
 -11.4%
H
39.4
81.4
|
| Emergent Biosolutions Inc |
|
595.6
|
11.3
|
L
 -4.7%
H
11.3
12.1
|
L
 -5.1%
H
11.3
12.3
|
L
 -6.7%
H
10.6
14.1
|
L
 -11.7%
H
9.0
14.1
|
L
 2.1%
H
4.0
14.1
|
L
 -12.2%
H
1.4
16.7
|
L
 -89.4%
H
1.4
127.2
|
L
 -67.2%
H
1.4
137.6
|
| GSK PLC (ADR) |
|
104,080.4
|
51.6
|
L
 1.9%
H
51.1
51.7
|
L
 5.0%
H
49.6
51.7
|
L
 4.7%
H
47.6
51.7
|
L
 9.9%
H
45.8
51.7
|
L
 45.9%
H
32.4
51.7
|
L
 46.9%
H
31.7
51.7
|
L
 36.1%
H
28.5
51.7
|
L
 22.8%
H
28.5
51.7
|
| Johnson & Johnson |
|
547,512.3
|
227.3
|
L
 0.0%
H
225.3
228.5
|
L
 3.2%
H
220
230
|
L
 9.8%
H
200.9
230
|
L
 20.2%
H
185.1
230
|
L
 48.7%
H
141.5
230
|
L
 40.3%
H
140.7
230
|
L
 39.3%
H
140.7
230
|
L
 117.6%
H
99.8
230
|
| Eli Lilly |
|
928,268.7
|
1,037.2
|
L
 1.3%
H
1020
1048.6
|
L
 -2.6%
H
1004.1
1073.4
|
L
 -4.0%
H
1004.1
1134.0
|
L
 22.8%
H
834.2
1134.0
|
L
 26.0%
H
623.8
1134.0
|
L
 204.6%
H
309.2
1134.0
|
L
 398.7%
H
178.6
1134.0
|
L
 1211.2%
H
64.2
1134.0
|
| Merck & Company |
|
273,692.6
|
110.3
|
L
 1.8%
H
108.0
110.5
|
L
 1.9%
H
106.0
110.5
|
L
 4.0%
H
104.4
112.9
|
L
 27.8%
H
82.0
112.9
|
L
 11.4%
H
73.3
112.9
|
L
 3.9%
H
73.3
134.6
|
L
 49.9%
H
68.4
134.6
|
L
 128.1%
H
45.8
134.6
|
| Novo Nordisk (ADR) |
|
264,076.0
|
59.4
|
L
 0.2%
H
58.6
59.9
|
L
 -4.6%
H
58.6
64
|
L
 16.0%
H
50.6
64.2
|
L
 18.8%
H
43.1
64.2
|
L
 -30.4%
H
43.1
93.8
|
L
 -14.5%
H
43.1
148.2
|
L
 70.8%
H
33.3
148.2
|
L
 112.8%
H
15.5
148.2
|
| Novartis AG (ADR) |
|
285,286.0
|
148.7
|
L
 -0.2%
H
148.1
150.0
|
L
 1.1%
H
146.8
152.5
|
L
 7.2%
H
135.6
152.5
|
L
 21.3%
H
122.6
152.5
|
L
 41.9%
H
97.7
152.5
|
L
 65.9%
H
80.0
152.5
|
L
 64.3%
H
74.1
152.5
|
L
 115.7%
H
59.2
152.5
|
| Organon & Co. |
|
2,220.3
|
8.5
|
L
 -0.7%
H
8.1
8.6
|
L
 -12.5%
H
8.1
9.7
|
L
 19.8%
H
7.1
9.9
|
L
 30.0%
H
6.3
9.9
|
L
 -46.5%
H
6.2
17.2
|
L
 -71.1%
H
6.2
30.5
|
L
H
6.2
39.5
|
L
H
6.2
39.5
|
| Prestige Consumer Healthcare Inc |
|
3,100.0
|
64.5
|
L
 0.9%
H
63.4
65.0
|
L
 -2.0%
H
62.7
66.1
|
L
 3.6%
H
60.2
68.3
|
L
 7.0%
H
57.3
68.3
|
L
 -17.8%
H
57.3
90.0
|
L
 -1.6%
H
56.0
90.0
|
L
 61.2%
H
39.4
90.0
|
L
 38.1%
H
26.3
90.0
|
| Pfizer |
|
150,330.1
|
26.4
|
L
 1.3%
H
25.9
26.5
|
L
 3.1%
H
25.6
26.8
|
L
 5.8%
H
24.8
26.8
|
L
 8.9%
H
23.9
26.8
|
L
 -1.8%
H
20.9
27.7
|
L
 -39.3%
H
20.9
44.5
|
L
 -26.4%
H
20.9
61.7
|
L
 -8.4%
H
20.9
61.7
|
| Perrigo Co PLC |
|
1,955.6
|
14.2
|
L
 3.4%
H
13.7
14.3
|
L
 -3.5%
H
13.6
14.9
|
L
 1.9%
H
13.6
15.4
|
L
 -31.2%
H
12.2
21.0
|
L
 -43%
H
12.2
30.9
|
L
 -62.0%
H
12.2
40.3
|
L
 -66.7%
H
12.2
50.9
|
L
 -90.2%
H
12.2
147.6
|
| Dr. Reddy`s Laboratories Ltd (ADR) |
|
11,173.1
|
13.4
|
L
 1.1%
H
13.3
13.5
|
L
 -1.9%
H
13.1
13.8
|
L
 -4.6%
H
12.8
14.2
|
L
 -0.2%
H
12.8
14.3
|
L
 -2.8%
H
12.3
16.2
|
L
 25.4%
H
10.5
74.9
|
L
 9.5%
H
9.6
74.9
|
L
 49.3%
H
5.6
74.9
|
| Takeda pharma Co (ADR) |
|
54,403.6
|
17.2
|
L
 0.4%
H
17.0
17.2
|
L
 5.8%
H
16.4
17.3
|
L
 10.2%
H
15.5
17.3
|
L
 30.2%
H
13.4
17.3
|
L
 25.8%
H
13.0
17.3
|
L
 8.4%
H
12.6
17.3
|
L
 -2.3%
H
12.3
20.0
|
L
 -27.7%
H
12.3
30.6
|
| Teva- pharma Ind Ltd (ADR) |
|
39,099.4
|
34.1
|
L
 3.1%
H
32.4
34.1
|
L
 7.1%
H
30.9
34.1
|
L
 8.7%
H
30.5
34.1
|
L
 70.1%
H
20.0
34.1
|
L
 91.0%
H
12.5
34.1
|
L
 232.2%
H
7.1
34.1
|
L
 189.3%
H
6.8
34.1
|
L
 -44.6%
H
6.1
62.8
|
| Zoetis (Class A) |
|
55,007.3
|
124.8
|
L
 2.6%
H
120.1
124.9
|
L
 0.6%
H
120.1
126.3
|
L
 -1.3%
H
120.1
131.1
|
L
 -13.1%
H
115.3
144.8
|
L
 -27.7%
H
115.3
177.4
|
L
 -24.2%
H
115.3
201.9
|
L
 -19.1%
H
115.3
249.3
|
L
 189.9%
H
38.3
249.3
|
| Biohaven Ltd |
|
1,569.7
|
11.8
|
L
 -2.2%
H
11.5
12.3
|
L
 -12.4%
H
11.5
13.4
|
L
 1.6%
H
9.3
14.0
|
L
 -32.0%
H
7.5
17.8
|
L
 -69.7%
H
7.5
44.3
|
L
 -36.3%
H
7.5
62.2
|
L
H
5.5
62.2
|
L
H
5.5
62.2
|
| Abeona Therapeutics Inc |
|
275.8
|
5.1
|
L
 0.2%
H
5.0
5.2
|
L
 -1.4%
H
4.8
5.3
|
L
 -1.7%
H
4.8
5.7
|
L
 0.2%
H
4
5.7
|
L
 -7.0%
H
3.9
7.5
|
L
 102.0%
H
2.2
9.0
|
L
 -89.3%
H
2.2
94.8
|
L
 -92.2%
H
2.2
568.8
|
| Oruka Therapeutics Inc |
|
1,657.0
|
34.2
|
L
 -2.9%
H
32.9
35.5
|
L
 -0.5%
H
32.9
36.3
|
L
 17.6%
H
25.2
36.5
|
L
 21.8%
H
25.2
36.5
|
L
 170.2%
H
5.5
36.5
|
L
 30.3%
H
2.2
53.9
|
L
 -32.1%
H
2.2
66
|
L
 -95.8%
H
2.2
939.6
|
| Acumen Pharma Inc |
|
157.5
|
2.6
|
L
 -6.8%
H
2.5
2.8
|
L
 31.3%
H
2.0
3.1
|
L
 30%
H
1.7
3.1
|
L
 17.1%
H
1.5
3.1
|
L
 66.7%
H
0.9
3.1
|
L
 -51.2%
H
0.9
11.3
|
L
H
0.9
27.0
|
L
H
0.9
27.0
|
| Arbutus Biopharma Corp |
|
794.3
|
4.1
|
L
H
4.1
4.2
|
L
 1.7%
H
4.0
4.2
|
L
 -10.6%
H
3.7
5.1
|
L
 -14.7%
H
3.7
5.1
|
L
 25.2%
H
2.7
5.1
|
L
 40%
H
1.7
5.1
|
L
 9.3%
H
1.7
6.5
|
L
 31.5%
H
0.8
12.6
|
| ABVC BioPharma Inc |
|
49.1
|
2.0
|
L
 -2.9%
H
2.0
2.1
|
L
 -1.9%
H
2
2.1
|
L
 -6.1%
H
2.0
2.4
|
L
 -28.4%
H
2.0
3.1
|
L
 288.5%
H
0.4
5.5
|
L
 -72.3%
H
0.4
9.6
|
L
 -96.0%
H
0.4
299.5
|
L
 -99.9%
H
0.4
378
|
| Acadia Pharma Inc |
|
4,251.5
|
25.1
|
L
 -2.2%
H
25.1
25.8
|
L
 -6.4%
H
25.1
27.2
|
L
 -5.9%
H
25.1
27.8
|
L
 10.5%
H
20.6
28.4
|
L
 34.5%
H
13.4
28.4
|
L
 35.6%
H
13.4
33.9
|
L
 -47.7%
H
12.2
52.8
|
L
 21.5%
H
12.2
58.7
|
| Adicet Bio Inc |
|
76.7
|
8.0
|
L
 -6%
H
7.9
8.5
|
L
 -5.3%
H
7.9
9
|
L
 0.8%
H
7.7
9.1
|
L
 -35.9%
H
7.4
12.9
|
L
 -43.9%
H
7.2
17.4
|
L
 -94.3%
H
7.2
152.4
|
L
 -95.9%
H
7.2
349.9
|
L
H
7.2
349.9
|
| Achieve Life Sciences Inc |
|
222.5
|
4.2
|
L
 -3.7%
H
4.2
4.5
|
L
 -25.4%
H
4.2
5.5
|
L
 -11.1%
H
4.2
6.0
|
L
 -20.2%
H
3.8
6.0
|
L
 29.0%
H
1.8
6.0
|
L
 -13.8%
H
1.8
10.3
|
L
 -65.7%
H
1.8
16.1
|
L
 -99.7%
H
1.8
3123.8
|
| AC Immune SA |
|
320.9
|
3.2
|
L
 -6.2%
H
3.2
3.4
|
L
 -13.8%
H
3.2
3.8
|
L
 1.3%
H
3.1
3.9
|
L
 -5.6%
H
2.5
3.9
|
L
 18.2%
H
1.4
4
|
L
 33.5%
H
1.4
5.1
|
L
 -46.7%
H
1.4
12.6
|
L
H
1.4
20.0
|
| Aclaris Therapeutics Inc |
|
380.3
|
3.5
|
L
 2.3%
H
3.5
3.8
|
L
 -22%
H
3.4
4.6
|
L
 21.0%
H
2.5
4.9
|
L
 41.0%
H
2.1
4.9
|
L
 46.9%
H
1.1
4.9
|
L
 -79.2%
H
0.6
17.6
|
L
 -83.1%
H
0.6
30.4
|
L
 -84.2%
H
0.6
33.3
|
| Acrivon Therapeutics Inc |
|
56.5
|
1.8
|
L
 -4.8%
H
1.8
1.9
|
L
 -12.7%
H
1.8
2.1
|
L
 -26.6%
H
1.6
3.6
|
L
 -7.7%
H
1.6
3.6
|
L
 -69.1%
H
1.1
8
|
L
 -87.6%
H
1.1
25.5
|
L
H
1.1
25.5
|
L
H
1.1
25.5
|
| Acelrx Pharma Inc |
|
16.3
|
1.0
|
L
 -1.0%
H
0.9
1.0
|
L
 -4%
H
0.9
1.0
|
L
 -11.1%
H
0.9
1.3
|
L
 -22.6%
H
0.9
1.6
|
L
 92%
H
0.4
1.6
|
L
 -51.0%
H
0.4
2.3
|
L
 -97.8%
H
0.4
58.8
|
L
 -98.7%
H
0.4
115
|
| Grace Therapeutics Inc |
|
56.2
|
3.6
|
L
 3.4%
H
3.5
3.7
|
L
 -5.0%
H
3.5
3.9
|
L
 7.7%
H
3.4
3.9
|
L
 13.8%
H
3.0
3.9
|
L
 14.2%
H
1.8
3.9
|
L
 -17.1%
H
1.7
5.0
|
L
 -88.4%
H
1.7
58.6
|
L
 -95.2%
H
1.7
161.1
|
| Acurx Pharma Inc |
|
5.5
|
2.4
|
L
 -5.6%
H
2.3
2.6
|
L
 -14.2%
H
2.3
2.8
|
L
 -9.9%
H
2.3
3.5
|
L
 -53.7%
H
2.3
5.8
|
L
 -84.5%
H
2.3
21
|
L
 -96.8%
H
2.3
176.4
|
L
H
2.3
176.4
|
L
H
2.3
176.4
|
| Adial Pharma Inc |
|
5.8
|
0.2
|
L
H
0.2
0.2
|
L
 -8.7%
H
0.2
0.2
|
L
 -8.7%
H
0.2
0.3
|
L
 -41.7%
H
0.2
0.4
|
L
 -74.7%
H
0.2
1.3
|
L
 -97.5%
H
0.2
15
|
L
 -99.6%
H
0.2
127
|
L
H
0.2
236
|
| Agios Pharma Inc |
|
1,600.1
|
27.4
|
L
 -0.6%
H
27.0
27.9
|
L
 -3.9%
H
27.0
29.9
|
L
 0.4%
H
26.3
29.9
|
L
 -36.5%
H
22.2
46
|
L
 -20.6%
H
22.2
46
|
L
 -6.0%
H
19.8
62.6
|
L
 -41.6%
H
16.8
62.6
|
L
 -35.0%
H
16.8
99.8
|
| Akebia Therapeutics Inc |
|
374.2
|
1.4
|
L
 -2.8%
H
1.4
1.5
|
L
 3.7%
H
1.4
1.5
|
L
 -11.3%
H
1.3
1.6
|
L
 -32.9%
H
1.3
2.2
|
L
 -38.7%
H
1.3
4.1
|
L
 135%
H
0.5
4.1
|
L
 -56.5%
H
0.2
5.1
|
L
 -80.8%
H
0.2
20.3
|
| Aligos Therapeutics Inc |
|
49.7
|
8.1
|
L
 -0.6%
H
7.7
8.2
|
L
 -0.6%
H
7.7
9.0
|
L
 -11.5%
H
7.6
10.5
|
L
 -1.6%
H
5.8
13.7
|
L
 -66.0%
H
3.8
29.5
|
L
 -82.7%
H
3.8
52.5
|
L
 -98.9%
H
3.8
875
|
L
H
3.8
937.8
|
| Alkermes PLC |
|
5,595.8
|
33.9
|
L
 -2.8%
H
33.8
35.0
|
L
 0.8%
H
32.5
35.3
|
L
 21.9%
H
27.5
35.3
|
L
 10.0%
H
27.5
36.3
|
L
 6.2%
H
25.2
36.5
|
L
 17.7%
H
22.0
36.5
|
L
 61.5%
H
18.0
36.5
|
L
 5.9%
H
12.0
71.2
|
| Allarity Therapeutics Inc |
|
16.1
|
1
|
L
 -3.9%
H
1
1.0
|
L
 -16.7%
H
1
1.2
|
L
 -1.0%
H
1
1.3
|
L
 -28.6%
H
1.0
1.5
|
L
 -15.3%
H
0.6
2.1
|
L
 -100.0%
H
0.1
7560
|
L
H
0.1
509600
|
L
H
0.1
509600
|
| Alnylam Pharma Inc |
|
44,662.4
|
338.1
|
L
 -2.5%
H
336.4
346.5
|
L
 -5.6%
H
336.4
368.1
|
L
 -14.9%
H
336.4
427.1
|
L
 -24.8%
H
336.4
479.8
|
L
 22.0%
H
205.9
495.6
|
L
 50.0%
H
142.0
495.6
|
L
 124.7%
H
117.6
495.6
|
L
 390.4%
H
31.4
495.6
|
| Rein Therapeutics Inc |
|
34.2
|
1.3
|
L
 -9.1%
H
1.3
1.4
|
L
 -5.1%
H
1.3
1.6
|
L
 21.5%
H
1.1
1.6
|
L
 -16.1%
H
1.0
2.2
|
L
 -34.3%
H
1.0
3.0
|
L
 -52.7%
H
1.0
7.4
|
L
 -96.4%
H
1.0
46
|
L
H
1.0
309.6
|
| Alzamend Neuro Inc |
|
8.2
|
2.2
|
L
 6.4%
H
2.0
2.2
|
L
 -2.3%
H
2.0
2.3
|
L
 12.0%
H
1.7
2.5
|
L
 -17.6%
H
1.7
2.7
|
L
 -79.2%
H
1.7
10.7
|
L
 -99.8%
H
1.7
1071.9
|
L
H
1.7
45292.5
|
L
H
1.7
45292.5
|
| Amylyx Pharma Inc |
|
1,569.3
|
14.3
|
L
 -3.8%
H
14.0
15
|
L
 -9.3%
H
14.0
15.8
|
L
 19.1%
H
10.8
17.5
|
L
 1.7%
H
10.8
17.5
|
L
 307.1%
H
2.6
17.5
|
L
 -63.1%
H
1.6
40.9
|
L
H
1.6
41.9
|
L
H
1.6
41.9
|
| Amphastar Pharma Inc |
|
1,217.3
|
26.5
|
L
 1.3%
H
26.0
26.6
|
L
 2.2%
H
25.6
26.7
|
L
 -1.9%
H
25.4
29.5
|
L
 7.4%
H
23.7
29.5
|
L
 -27.2%
H
20.4
36.4
|
L
 -12.5%
H
20.4
67.7
|
L
 45.7%
H
16.9
67.7
|
L
 119.8%
H
10.5
67.7
|
| Anebulo Pharma Inc |
|
42.8
|
1.1
|
L
 19.3%
H
0.9
1.1
|
L
 -1.9%
H
0.8
1.1
|
L
 7.1%
H
0.8
1.2
|
L
 -60.2%
H
0.8
2.7
|
L
 -34.0%
H
0.8
3.4
|
L
 -56.3%
H
0.8
4.1
|
L
H
0.8
9.3
|
L
H
0.8
9.3
|
| Annexon Inc |
|
930.1
|
6.2
|
L
 -4.3%
H
6.2
6.8
|
L
 -8.0%
H
6.2
6.8
|
L
 23.8%
H
4.5
7.2
|
L
 113.0%
H
2.5
7.2
|
L
 54.5%
H
1.3
7.2
|
L
 -12.1%
H
1.3
8.4
|
L
 -71.6%
H
1.3
38.0
|
L
H
1.3
38.0
|
| Apollomics Inc (Class A) |
|
39.2
|
18.3
|
L
 2.1%
H
17.8
18.9
|
L
 1.7%
H
17.5
20.5
|
L
 -11.5%
H
17.5
23.0
|
L
 57.6%
H
11.3
27.0
|
L
 104.7%
H
3.7
42.1
|
L
 -98.2%
H
0.1
4900
|
L
H
0.1
4900
|
L
H
0.1
4900
|
| Apellis Pharma Inc |
|
2,856.9
|
22.6
|
L
 -2.0%
H
21.8
23.4
|
L
 3.8%
H
21.1
23.8
|
L
 -10.5%
H
19.3
27.5
|
L
 8.9%
H
18.8
27.5
|
L
 -25.7%
H
16.1
30.6
|
L
 -57.2%
H
16.1
94.8
|
L
 -49.0%
H
16.1
94.8
|
L
H
11.5
94.8
|
| Applied Therapeutics Inc |
|
14.4
|
0.1
|
L
H
0.1
0.1
|
L
H
0.1
0.1
|
L
H
0.1
0.1
|
L
 -91.2%
H
0.1
1.2
|
L
 -83.1%
H
0.1
1.5
|
L
 -91.5%
H
0.1
10.6
|
L
 -99.5%
H
0.1
29.8
|
L
H
0.1
57.4
|
| Aptorum Grp Ltd (Class A) |
|
7.7
|
1.0
|
L
 15.9%
H
0.8
1.0
|
L
 -1.0%
H
0.8
1.0
|
L
 -14.4%
H
0.8
1.1
|
L
 -35.4%
H
0.8
1.7
|
L
 -22.8%
H
0.7
4.5
|
L
 -81.3%
H
0.5
17.5
|
L
 -97.0%
H
0.5
45.6
|
L
H
0.5
332.8
|
| Aprea Therapeutics Inc |
|
5.6
|
0.8
|
L
 35.6%
H
0.6
1.5
|
L
 -3.6%
H
0.6
1.5
|
L
 -10.1%
H
0.6
1.5
|
L
 -44.8%
H
0.6
1.5
|
L
 -79.0%
H
0.6
4.7
|
L
 -91.9%
H
0.6
11.3
|
L
 -99.3%
H
0.6
169.2
|
L
H
0.6
1062.2
|
| Aquestive Therapeutics Inc |
|
359.9
|
3.0
|
L
 -6.7%
H
2.9
3.2
|
L
 -9.0%
H
2.9
3.5
|
L
 -53.8%
H
2.9
6.6
|
L
 -55.7%
H
2.9
6.9
|
L
 -4.2%
H
2.1
7.6
|
L
 235.2%
H
0.7
7.6
|
L
 -44.2%
H
0.6
7.6
|
L
H
0.6
20.7
|
| Arcturus Therapeutics Holdings Inc |
|
212.3
|
7.5
|
L
 -1.3%
H
7.2
7.6
|
L
 -0.8%
H
7.2
7.7
|
L
 20.7%
H
6.0
7.9
|
L
 -22.4%
H
5.9
10.1
|
L
 -57.1%
H
5.9
24.2
|
L
 -63.1%
H
5.9
45
|
L
 -89.7%
H
5.9
89.2
|
L
 -79.2%
H
4.1
129.7
|
| Ardelyx Inc |
|
1,868.5
|
7.7
|
L
 -2.0%
H
7.6
7.9
|
L
 -1.0%
H
7.6
8.1
|
L
 32.6%
H
5.5
8.4
|
L
 53.5%
H
5.3
8.4
|
L
 43.5%
H
3.2
8.4
|
L
 176.6%
H
2.8
10.1
|
L
 13.3%
H
0.5
10.1
|
L
 -26.1%
H
0.5
16.3
|
| Arcutis Biotherapeutics Inc |
|
3,107.6
|
25.4
|
L
 -1.4%
H
25.0
25.6
|
L
 -3.2%
H
25.0
27.0
|
L
 -9.7%
H
25.0
30.8
|
L
 1.8%
H
22.3
31.8
|
L
 85.6%
H
11.1
31.8
|
L
 58.1%
H
1.8
31.8
|
L
 -7.0%
H
1.8
38.5
|
L
H
1.8
40.9
|
| Artelo Biosciences Inc |
|
3.5
|
1.7
|
L
 1.8%
H
1.6
1.8
|
L
 -1.2%
H
1.6
1.9
|
L
 47.4%
H
1.2
1.9
|
L
 -44.8%
H
1.2
3.4
|
L
 -75.6%
H
1.2
28.6
|
L
 -91.0%
H
1.2
28.6
|
L
 -98.0%
H
1.2
330.3
|
L
H
1.2
15552
|
| Assembly Biosciences Inc |
|
407.8
|
25.8
|
L
 0.3%
H
24.7
26.1
|
L
 -8.0%
H
24.7
28.6
|
L
 -19.8%
H
24.7
34.7
|
L
 -14.4%
H
24.7
39.7
|
L
 78.7%
H
7.8
39.7
|
L
 27.1%
H
7.7
39.7
|
L
 -61.5%
H
7.7
84.2
|
L
 -58.0%
H
7.7
808.3
|
| ASP Isotopes Inc |
|
793.2
|
6.3
|
L
 -12.4%
H
6.3
7.2
|
L
 -25.2%
H
6.3
8.6
|
L
 17.0%
H
5.2
8.6
|
L
 -41.1%
H
5.2
10.8
|
L
 3.4%
H
3.7
14.5
|
L
 311.7%
H
0.3
14.5
|
L
H
0.3
14.5
|
L
H
0.3
14.5
|
| Assertio Holdings Inc |
|
75.6
|
11.8
|
L
 0.4%
H
11.4
12
|
L
 2.4%
H
11.1
12.5
|
L
 28.0%
H
8.6
12.5
|
L
 4.4%
H
8.6
14.3
|
L
 -4.9%
H
7.7
15.2
|
L
 -80.5%
H
7.7
120.2
|
L
 -68.9%
H
7.7
120.2
|
L
 -98.7%
H
7.7
1621.2
|
| ATAI Life Sciences N.V. |
|
1,365.7
|
3.8
|
L
 -2.1%
H
3.7
3.9
|
L
 -9.4%
H
3.7
4.1
|
L
 -5.5%
H
3.5
4.2
|
L
 -35.0%
H
3.5
5.9
|
L
 135%
H
1.2
6.8
|
L
 116.1%
H
1.0
6.8
|
L
H
1.0
22.9
|
L
H
1.0
22.9
|
| ETHZilla Corp |
|
81.6
|
4.3
|
L
 -7.5%
H
4.2
4.7
|
L
 -18.1%
H
4.2
5.2
|
L
 -14.0%
H
4.2
5.7
|
L
 -78.6%
H
4.2
21.1
|
L
 -70.2%
H
4.2
174.6
|
L
 -99.3%
H
4.2
834.1
|
L
 -100.0%
H
4.2
49571
|
L
H
4.2
49571
|
| Atossa Therapeutics Inc |
|
4.8
|
0.6
|
L
 -6.7%
H
0.5
0.6
|
L
 -12.5%
H
0.5
0.7
|
L
 -9.7%
H
0.5
0.7
|
L
 -36.4%
H
0.5
1.0
|
L
 -34.9%
H
0.5
1.3
|
L
 -30%
H
0.5
2.3
|
L
 -74.7%
H
0.5
9.8
|
L
 -98.8%
H
0.5
127.8
|
| Atara Biotherapeutics Inc |
|
37.5
|
5.2
|
L
 -5.6%
H
4.9
5.6
|
L
 -0.4%
H
4.9
5.7
|
L
 -70.9%
H
4.2
19.1
|
L
 -63.0%
H
4.2
19.1
|
L
 -38.8%
H
4.2
19.1
|
L
 -95.7%
H
0.4
141
|
L
 -98.9%
H
0.4
546.3
|
L
 -98.9%
H
0.4
1361.3
|
| Atea Pharma Inc |
|
331.3
|
4.2
|
L
 8.4%
H
3.8
4.3
|
L
 2.9%
H
3.8
4.3
|
L
 19.4%
H
3.3
4.3
|
L
 29.7%
H
2.9
4.3
|
L
 41.8%
H
2.5
4.3
|
L
 -8.0%
H
2.5
5.2
|
L
 -94.2%
H
2.5
94.2
|
L
H
2.5
94.2
|
| Avalo Therapeutics Inc |
|
279.7
|
15.1
|
L
 -0.9%
H
14.6
15.3
|
L
 -4.1%
H
14.5
16.1
|
L
 -15.2%
H
14.5
18.5
|
L
 -16.2%
H
14.0
20.7
|
L
 91.3%
H
3.4
20.7
|
L
 287.4%
H
0.0
34.5
|
L
 -60.0%
H
0.0
54
|
L
 -59.9%
H
0.0
91.8
|
| Aytu BioPharma Inc |
|
26.5
|
2.6
|
L
 0.8%
H
2.5
2.7
|
L
 -3.7%
H
2.5
2.8
|
L
 2.0%
H
2.5
3.1
|
L
 17.7%
H
1.8
3.1
|
L
 54.8%
H
1.0
3.1
|
L
 -21.2%
H
1.0
3.5
|
L
 -98.2%
H
1.0
235.3
|
L
 -100.0%
H
1.0
950400
|
| Adagene Inc (ADR) |
|
129.6
|
2.8
|
L
 -5.5%
H
2.4
2.9
|
L
 10.4%
H
2.1
2.9
|
L
 51.1%
H
1.5
2.9
|
L
 43.2%
H
1.3
2.9
|
L
 48.7%
H
1.3
3.2
|
L
 46.3%
H
1.1
4.4
|
L
H
0.9
31.8
|
L
H
0.9
31.8
|
| Addex Therapeutics Ltd (ADR) |
|
9.4
|
7.7
|
L
 -7.0%
H
7.6
7.7
|
L
 -4.3%
H
7.6
8.2
|
L
 -1.0%
H
7
10.4
|
L
 -17.2%
H
7
10.4
|
L
 4.8%
H
6.5
12.1
|
L
 -63.2%
H
5
45.6
|
L
 -96.4%
H
5
252.9
|
L
H
5
750.4
|
| Amarin Corp (ADR) |
|
310.2
|
14.9
|
L
 -3.2%
H
14.6
15.5
|
L
 -8.2%
H
14.6
16.2
|
L
 10.4%
H
13.1
17.3
|
L
 -9.0%
H
13.1
17.3
|
L
 2472.4%
H
0.4
20.9
|
L
 724.3%
H
0.4
20.9
|
L
 98.9%
H
0.4
20.9
|
L
 997.1%
H
0.4
26.1
|
| Ascendis Pharma A/S (ADR) |
|
13,814.3
|
226.1
|
L
 1.0%
H
221.5
228.5
|
L
 -4.0%
H
220.5
242
|
L
 8.0%
H
188.1
242
|
L
 11.0%
H
188.1
242
|
L
 77.6%
H
118.0
242
|
L
 87.2%
H
64.3
242
|
L
 50.6%
H
61.6
242
|
L
 1087.5%
H
11.9
242
|
| Alterity Therapeutics Ltd (ADR) |
|
57.5
|
3.2
|
L
 -2.8%
H
3.1
3.3
|
L
 -10.7%
H
3.1
3.8
|
L
 3.6%
H
3.0
3.8
|
L
 -31.1%
H
2.7
4.3
|
L
 -30.6%
H
2.5
7
|
L
 -23.6%
H
1
7
|
L
 -80.8%
H
1
27.5
|
L
 -90.0%
H
1
66.9
|
| Avadel Pharma PLC (ADR) |
|
2,115.2
|
21.6
|
L
 -0.1%
H
21.5
21.6
|
L
 0.2%
H
21.5
21.7
|
L
 0.1%
H
21.4
21.7
|
L
 14.5%
H
18.7
23.6
|
L
 180.2%
H
6.4
23.6
|
L
 203.1%
H
6.4
23.6
|
L
 195.2%
H
1.1
23.6
|
L
 112.1%
H
1.0
23.6
|
| Astrazeneca PLC (ADR) |
|
287,639.6
|
92.8
|
L
 0.2%
H
92.5
93.5
|
L
 -0.2%
H
92.5
96.2
|
L
 0.3%
H
89.0
96.5
|
L
 12.7%
H
80.5
96.5
|
L
 30.2%
H
61.2
96.5
|
L
 40.9%
H
60.5
96.5
|
L
 83.3%
H
46.5
96.5
|
L
 187.9%
H
25.6
96.5
|
| Biofrontera Inc |
|
10.8
|
0.9
|
L
 -6.1%
H
0.9
1.0
|
L
 -7%
H
0.9
1.0
|
L
 29.2%
H
0.6
1.0
|
L
 -13.1%
H
0.6
1.2
|
L
 -12.3%
H
0.5
1.2
|
L
 -94.8%
H
0.5
19.2
|
L
H
0.5
292.6
|
L
H
0.5
292.6
|
| Biomea Fusion Inc |
|
79.2
|
1.1
|
L
 -5.1%
H
1.1
1.2
|
L
 -16.4%
H
1.1
1.3
|
L
 -8.2%
H
1.1
1.7
|
L
 -15.8%
H
0.9
1.7
|
L
 -73.7%
H
0.9
4.3
|
L
 -88.4%
H
0.9
43.7
|
L
H
0.9
43.7
|
L
H
0.9
43.7
|
| Bolt Biotherapeutics Inc |
|
11.3
|
5.9
|
L
 -5.6%
H
5.9
6.4
|
L
 -11.7%
H
5.9
7.1
|
L
 11.3%
H
5.2
7.2
|
L
 3.0%
H
4.4
7.2
|
L
 -41.4%
H
4.4
10.5
|
L
 -79.1%
H
4.4
40.6
|
L
H
4.4
861.4
|
L
H
4.4
861.4
|
| Blue Water Biotech Inc |
|
25.3
|
1.4
|
L
 -4.7%
H
1.3
1.5
|
L
 -10.1%
H
1.3
1.7
|
L
 -0.7%
H
1.3
2.3
|
L
 -62.5%
H
1.3
3.7
|
L
 1675%
H
0.1
5.9
|
L
 10.1%
H
0.1
5.9
|
L
H
0.1
90.9
|
L
H
0.1
90.9
|
| BeyondSpring Inc |
|
63.3
|
1.5
|
L
 -1.3%
H
1.5
1.6
|
L
 -4.9%
H
1.5
1.7
|
L
 -9.9%
H
1.4
1.8
|
L
 -19.4%
H
1.4
2.4
|
L
 -12.5%
H
1.0
3.4
|
L
 -39.6%
H
0.7
4
|
L
 -87.3%
H
0.5
33
|
L
H
0.5
48.5
|
| Biodexa Pharma PLC (ADR) |
|
1.5
|
1.8
|
L
 -3.8%
H
1.7
1.8
|
L
 -17.7%
H
1.7
2.3
|
L
 -23.0%
H
1.7
2.6
|
L
 -71.0%
H
1.7
8.9
|
L
 -95.8%
H
1.7
92
|
L
 -100.0%
H
1.7
1680000
|
L
 -100.0%
H
1.7
38295000
|
L
 -100.0%
H
1.7
2720000000
|
| BeiGene Ltd (ADR) |
|
36,259.4
|
340.4
|
L
 -2.8%
H
339.2
350.0
|
L
 0.3%
H
334.4
353
|
L
 11.7%
H
302.6
353.1
|
L
 10.4%
H
299.5
385.2
|
L
 49.0%
H
228.9
385.2
|
L
 32.9%
H
127.0
385.2
|
L
 6.4%
H
118.2
426.6
|
L
H
22.5
426.6
|
| Bioline Rx Ltd (ADR) |
|
13.5
|
3.1
|
L
 -1.9%
H
3
3.2
|
L
 0.3%
H
2.9
3.2
|
L
 8.4%
H
2.7
3.2
|
L
 -9.9%
H
2.7
3.9
|
L
 -12.9%
H
2.3
7.8
|
L
 -87.7%
H
0.1
101.2
|
L
 -97.2%
H
0.1
253.6
|
L
 -99.5%
H
0.1
1103.9
|
| Belite Bio Inc (ADR) |
|
6,340.0
|
169
|
L
 0.0%
H
160
169.3
|
L
 2.7%
H
160
174.8
|
L
 5.1%
H
146.1
174.8
|
L
 72.3%
H
98.0
174.8
|
L
 183.6%
H
49
174.8
|
L
 472.5%
H
11
174.8
|
L
H
6
174.8
|
L
H
6
174.8
|
| Neuphoria Therapeutics Inc |
|
21.6
|
4.0
|
L
H
4.0
4.0
|
L
 -4.1%
H
4.0
4.3
|
L
 7.8%
H
3.7
4.4
|
L
 -8.6%
H
3.6
5.2
|
L
 -25.7%
H
3.6
21.4
|
L
 0.2%
H
0.2
21.4
|
L
H
0.2
22
|
L
H
0.2
22
|
| Capricor Therapeutics Inc |
|
1,190.8
|
21.9
|
L
 -3.2%
H
21.8
23
|
L
 -5.7%
H
21.1
23.9
|
L
 -24.4%
H
21.1
29.4
|
L
 252.5%
H
4.3
40.4
|
L
 44.0%
H
4.3
40.4
|
L
 415.1%
H
2.7
40.4
|
L
 232.7%
H
2.6
40.4
|
L
 -18.0%
H
0.9
54
|
| CASI Pharma Inc |
|
21.0
|
1.0
|
L
 3.0%
H
1.0
1.0
|
L
 6.3%
H
1.0
1.0
|
L
 34.2%
H
0.8
1.2
|
L
 -25%
H
0.8
1.5
|
L
 -59.2%
H
0.8
3.1
|
L
 -51.0%
H
0.8
8.5
|
L
 -97.0%
H
0.8
36.8
|
L
 -90.6%
H
0.8
88.9
|
| Cullinan Oncology Inc |
|
706.6
|
12.0
|
L
 0.3%
H
11.5
12.3
|
L
 -4.3%
H
11.5
12.7
|
L
 20.6%
H
9.4
13.0
|
L
 58.2%
H
6.7
13.3
|
L
 8.9%
H
5.7
13.3
|
L
 5.7%
H
5.7
30.2
|
L
 -68.5%
H
5.7
59.9
|
L
H
5.7
59.9
|
| Coherus Biosciences Inc |
|
261.1
|
2.2
|
L
 -7.3%
H
2.1
2.4
|
L
 4.9%
H
2
2.6
|
L
 53.2%
H
1.4
2.6
|
L
 27.1%
H
1.1
2.6
|
L
 60%
H
0.7
2.6
|
L
 -73.5%
H
0.7
9.1
|
L
 -88.5%
H
0.7
21.6
|
L
 -83.7%
H
0.7
32.0
|
| Cingulate Inc |
|
42.7
|
5.7
|
L
 0.4%
H
5.5
5.9
|
L
 17.6%
H
4.8
6.7
|
L
 36.7%
H
4.1
6.7
|
L
 59%
H
3.2
6.7
|
L
 26.2%
H
3.2
6.7
|
L
 479.8%
H
0.2
20.8
|
L
H
0.2
20.8
|
L
H
0.2
20.8
|
| Clene Inc |
|
48.2
|
4.1
|
L
 -1.9%
H
4.1
4.4
|
L
 -23.0%
H
4.1
5.4
|
L
 -31.4%
H
4.1
6.7
|
L
 -59.1%
H
4.1
13.5
|
L
 -13.9%
H
2.3
13.5
|
L
 -87.2%
H
2.3
39.8
|
L
 -96.8%
H
2.3
356.4
|
L
H
0.5
356.4
|
| Cellectar Biosciences Inc |
|
13.7
|
3.2
|
L
 -0.6%
H
3.2
3.4
|
L
 -15.0%
H
3.2
3.7
|
L
 17.5%
H
2.7
4.1
|
L
 -1.2%
H
2.5
4.1
|
L
 -56.9%
H
2.5
20.6
|
L
 -93.2%
H
2.5
133.5
|
L
 -99.4%
H
2.5
894
|
L
 -100.0%
H
2.5
22200
|
| Clearmind Medicine Inc |
|
3.3
|
2.2
|
L
 -0.9%
H
2.1
2.4
|
L
 -20.8%
H
2.1
2.7
|
L
 16.7%
H
1.7
2.8
|
L
 -94.0%
H
1.7
33.6
|
L
 -96.0%
H
1.7
60
|
L
 -100.0%
H
1.7
6050.4
|
L
 -100.0%
H
1.7
788400
|
L
H
1.7
788400
|
| Compass Therapeutics Inc |
|
1,138.3
|
6.4
|
L
 0.3%
H
6.2
6.5
|
L
 8.5%
H
5.7
6.5
|
L
 19.0%
H
4.8
6.5
|
L
 72.0%
H
3.5
6.5
|
L
 111.9%
H
1.3
6.5
|
L
 66.2%
H
0.8
6.5
|
L
H
0.8
11
|
L
H
0.8
11
|
| Cns Pharma Inc |
|
3.5
|
5.6
|
L
 -3.6%
H
5.5
5.8
|
L
 -7.6%
H
5.5
6.4
|
L
 2.2%
H
5.2
8.9
|
L
 -25.7%
H
5.2
8.9
|
L
 -99.8%
H
4.9
5700
|
L
 -100.0%
H
4.9
6600000
|
L
 -100.0%
H
4.9
200700000
|
L
H
4.9
256050000
|
| Context Therapeutics Inc |
|
239.8
|
2.6
|
L
 5.7%
H
2.4
2.9
|
L
 44.2%
H
1.8
2.9
|
L
 100.8%
H
1.3
2.9
|
L
 131.0%
H
1
2.9
|
L
 171.9%
H
0.5
2.9
|
L
 283.8%
H
0.5
2.9
|
L
H
0.5
10.9
|
L
H
0.5
10.9
|
| Cocrystal Pharma Inc |
|
13.5
|
1.0
|
L
 -2%
H
1.0
1.0
|
L
 -5.8%
H
1.0
1.1
|
L
 3.2%
H
0.9
1.2
|
L
 -10.1%
H
0.9
1.2
|
L
 -50.8%
H
0.9
2.7
|
L
 -63.4%
H
0.9
3.3
|
L
 -95.3%
H
0.9
41.5
|
L
 -99.6%
H
0.9
309.6
|
| Collegium pharma Inc |
|
1,451.6
|
45.9
|
L
 1.3%
H
45.0
46.3
|
L
 0.9%
H
43.6
46.9
|
L
 -2.6%
H
43.6
49.2
|
L
 28.8%
H
35.2
50.8
|
L
 41.3%
H
23.2
50.8
|
L
 67.7%
H
20.8
50.8
|
L
 90.2%
H
14.0
50.8
|
L
 169.6%
H
7.4
50.8
|
| Corcept Therapeutics Inc |
|
4,193.9
|
39.9
|
L
 -10.6%
H
36.8
40.7
|
L
 -9.4%
H
36.8
47.1
|
L
 -43.2%
H
33.0
47.1
|
L
 -44.8%
H
33.0
89
|
L
 -43.0%
H
33.0
117.3
|
L
 73.4%
H
17.9
117.3
|
L
 41.1%
H
15.8
117.3
|
L
 992.3%
H
3.3
117.3
|
| Cosmos Health Inc |
|
17.9
|
0.5
|
L
 2.1%
H
0.5
0.5
|
L
 -4%
H
0.4
0.5
|
L
 -4%
H
0.4
0.6
|
L
 -46.7%
H
0.4
1.0
|
L
 -27.3%
H
0.3
1.3
|
L
 -92.0%
H
0.3
7.3
|
L
 -99.6%
H
0.3
225
|
L
 -99.6%
H
0.3
312.5
|
| Cumberland Pharma Inc |
|
56.1
|
3.8
|
L
 1.4%
H
3.6
4.0
|
L
 -4.6%
H
3.6
4.0
|
L
 -5.3%
H
3.6
5.4
|
L
 16.8%
H
1.9
5.4
|
L
 66.7%
H
1.9
7.3
|
L
 38.9%
H
1.0
7.3
|
L
 18.3%
H
1.0
7.5
|
L
 -24.4%
H
1.0
8.0
|
| Catalyst Pharma Inc |
|
2,986.8
|
24.3
|
L
 -1.1%
H
24.1
24.8
|
L
 3.1%
H
23.6
24.8
|
L
 4.3%
H
22.1
24.8
|
L
 15.9%
H
20.7
25.1
|
L
 4.8%
H
19.1
26.6
|
L
 54.6%
H
11.1
26.6
|
L
 567.6%
H
3.3
26.6
|
L
 1206.5%
H
0.5
26.6
|
| Corbus Pharma Holdings Inc |
|
145.2
|
8.3
|
L
 -4.2%
H
8.2
8.7
|
L
 -5.3%
H
8.2
9.6
|
L
 3.3%
H
7.6
9.6
|
L
 -49.7%
H
7.6
12.9
|
L
 -16.5%
H
4.6
20.6
|
L
 83.8%
H
2.1
61.9
|
L
 -84.9%
H
2.1
120
|
L
 -80.4%
H
2.1
323.4
|
| Crinetics Pharma Inc |
|
5,119.4
|
49.9
|
L
 -3.7%
H
49.3
53.0
|
L
 -6.1%
H
49.3
53.6
|
L
 5.4%
H
43.4
58.0
|
L
 15.4%
H
38.8
58.0
|
L
 24.0%
H
24.1
58.0
|
L
 161.5%
H
15.2
62.5
|
L
 248.0%
H
13.8
62.5
|
L
H
10.6
62.5
|
| Corvus Pharma Inc |
|
1,734.0
|
20.7
|
L
 -1.2%
H
20.2
21.7
|
L
 -17.5%
H
20.2
24.4
|
L
 176.4%
H
6.4
27.0
|
L
 166.8%
H
6.4
27.0
|
L
 291.3%
H
2.5
27.0
|
L
 2455.6%
H
0.6
27.0
|
L
 456.5%
H
0.6
27.0
|
L
H
0.6
27.0
|
| CytomX Therapeutics Inc |
|
964.1
|
5.7
|
L
 -0.9%
H
5.4
5.9
|
L
 2.7%
H
5.3
6.1
|
L
 36.8%
H
4.0
6.2
|
L
 70.9%
H
3.4
6.2
|
L
 546.6%
H
0.4
6.2
|
L
 112.3%
H
0.4
6.2
|
L
 -17.7%
H
0.4
10.1
|
L
 -63.8%
H
0.4
35
|
| Cyclacel Pharma Inc |
|
5.9
|
1.2
|
L
 -1.6%
H
1.2
1.3
|
L
 -8.3%
H
1.2
1.4
|
L
 -22.4%
H
1.2
1.7
|
L
 -33.5%
H
1.2
2.0
|
L
 -98.6%
H
1.2
100.8
|
L
 -100.0%
H
1.2
4212
|
L
 -100.0%
H
1.2
41112
|
L
 -100.0%
H
1.2
784800
|
| Cyclerion Therapeutics Inc |
|
5.2
|
1.4
|
L
 -0.7%
H
1.3
1.4
|
L
 -11.7%
H
1.3
1.5
|
L
 15.3%
H
1.2
2.3
|
L
 -29.2%
H
1.2
2.3
|
L
 -46.5%
H
1.2
6.3
|
L
 -89.4%
H
1.2
19.1
|
L
 -97.8%
H
1.2
138
|
L
H
1.2
457
|
| Cytokinetics Inc |
|
7,725.9
|
63.2
|
L
 -3.7%
H
62.8
65.7
|
L
 -0.4%
H
62.1
66.0
|
L
 3.0%
H
58.9
66.6
|
L
 1.5%
H
58.1
71.0
|
L
 26.5%
H
29.3
71.0
|
L
 53.9%
H
26.0
110
|
L
 221.3%
H
17.7
110
|
L
 720.6%
H
5.8
110
|
| Cellectis (ADR) |
|
380.2
|
3.8
|
L
 -5.0%
H
3.8
3.9
|
L
 -14.3%
H
3.8
4.3
|
L
 -20.7%
H
3.8
5.0
|
L
 8.9%
H
3.1
5.5
|
L
 139.9%
H
1.1
5.5
|
L
 25.9%
H
1.0
5.5
|
L
 -86.1%
H
1.0
30.1
|
L
 -83.1%
H
1.0
38.9
|
| Centessa Pharma PLC (ADR) |
|
3,631.9
|
24.6
|
L
 -1.3%
H
23.8
25.2
|
L
 -2.8%
H
23.8
26.6
|
L
 -0.7%
H
21.5
26.6
|
L
 1.0%
H
17.1
30.6
|
L
 45.3%
H
9.6
30.6
|
L
 544.9%
H
3
30.6
|
L
H
2.9
30.6
|
L
H
2.9
30.6
|
| Connect Biopharma Holdings Ltd (ADR) |
|
133.7
|
2.4
|
L
 -5.9%
H
2.4
2.5
|
L
 -5.5%
H
2.3
2.7
|
L
 -11.1%
H
2.0
2.9
|
L
 54.8%
H
1.5
3.3
|
L
 147.4%
H
0.5
3.3
|
L
 95.1%
H
0.5
3.3
|
L
H
0.5
29.3
|
L
H
0.5
29.3
|
| Dare Bioscience Inc |
|
25.9
|
1.8
|
L
 -4.7%
H
1.8
1.9
|
L
 -7.2%
H
1.8
2.0
|
L
 -7.7%
H
1.8
2.1
|
L
 -6.2%
H
1.6
2.5
|
L
 -43.6%
H
1.6
9.2
|
L
 -87.9%
H
0.3
15.5
|
L
 -93.3%
H
0.3
31.0
|
L
 -99.4%
H
0.3
519.6
|
| Day One Biopharma Inc |
|
1,145.9
|
11.2
|
L
H
11.0
11.5
|
L
 -6.6%
H
11.0
12.5
|
L
 21.6%
H
8.4
13.2
|
L
 58.5%
H
7.0
13.2
|
L
 -13.2%
H
5.6
13.2
|
L
 -47.7%
H
5.6
22.1
|
L
H
5.4
28.7
|
L
H
5.4
28.7
|
| Journey Medical Corp |
|
278.0
|
8.4
|
L
 -1.1%
H
8.3
8.6
|
L
 -3.7%
H
8.0
9.1
|
L
 9.7%
H
7.0
9.6
|
L
 0.6%
H
7.0
9.6
|
L
 110.1%
H
4.0
9.6
|
L
 322.2%
H
1.0
9.6
|
L
H
1.0
10.2
|
L
H
1.0
10.2
|
| Diffusion Pharma Inc |
|
-
|
5.2
|
L
 -0.4%
H
4.9
5.3
|
L
 -18.0%
H
4.9
6.4
|
L
 -35.5%
H
4.9
8.2
|
L
 -27.6%
H
4.9
10
|
L
 -41.3%
H
4.9
13.1
|
L
 -45.0%
H
4.1
14.4
|
L
 -94.0%
H
4.1
138.8
|
L
 -100.0%
H
4.1
17437.5
|
| DiaMedica Therapeutics Inc |
|
418.7
|
8.0
|
L
 -5.1%
H
7.9
8.6
|
L
 -5.5%
H
7.9
9
|
L
 -0.1%
H
7.2
9
|
L
 14.9%
H
5.3
10.4
|
L
 37.4%
H
3.2
10.4
|
L
 474.3%
H
1.3
10.4
|
L
 0.1%
H
1.1
10.9
|
L
 268.8%
H
1.1
13.8
|
| Dermata Therapeutics Inc |
|
6.4
|
2.3
|
L
 -19.9%
H
2.2
2.9
|
L
 3.7%
H
2.2
4.7
|
L
 -1.3%
H
1.8
4.7
|
L
 -34.4%
H
1.6
4.7
|
L
 87.5%
H
0.6
7.1
|
L
 -54.6%
H
0.2
7.1
|
L
H
0.2
111.2
|
L
H
0.2
111.2
|
| DBV Tech (ADR) |
|
1,173.3
|
21.6
|
L
 -5.9%
H
21.6
23.5
|
L
 -11.9%
H
21.6
24.7
|
L
 12.5%
H
16.5
25.4
|
L
 53.4%
H
12.6
26.2
|
L
 407.3%
H
3.8
26.2
|
L
 60.1%
H
0.5
26.2
|
L
 -58.0%
H
0.5
68.8
|
L
 -91.7%
H
0.5
505.7
|
| Edesa Biotech Inc |
|
9.8
|
1.2
|
L
 -4.9%
H
1.1
1.3
|
L
 -19.3%
H
1.1
1.5
|
L
 -22.5%
H
1.1
1.6
|
L
 -37.4%
H
1.1
2.0
|
L
 -38.1%
H
1.1
4.5
|
L
 -88.6%
H
1.1
11.2
|
L
 -97.1%
H
1.1
84
|
L
 -99.9%
H
1.1
2037.4
|
| Eledon Pharma Inc |
|
175.2
|
2.2
|
L
 2.3%
H
2.1
2.2
|
L
 2.8%
H
2.1
2.2
|
L
 45.7%
H
1.4
2.3
|
L
 -49.4%
H
1.4
4.6
|
L
 -54.0%
H
1.4
5.0
|
L
 -26.7%
H
1.1
5.4
|
L
 -85.2%
H
1.1
22.9
|
L
 -99.8%
H
1.1
1425.6
|
| Enanta Pharma Inc |
|
374.3
|
12.9
|
L
H
12.5
13.0
|
L
 -0.9%
H
12.5
13.3
|
L
 -18.9%
H
12.1
16.5
|
L
 18.8%
H
10.2
17.2
|
L
 151.0%
H
4.1
17.2
|
L
 -74.7%
H
4.1
62.1
|
L
 -73.2%
H
4.1
102
|
L
 -49.8%
H
4.1
127.8
|
| Entera Bio Ltd |
|
62.8
|
1.4
|
L
 -6.2%
H
1.4
1.5
|
L
 -14.4%
H
1.4
1.6
|
L
 -31.5%
H
1.4
2.0
|
L
 -51.4%
H
1.4
3.2
|
L
 -41.2%
H
1.4
3.2
|
L
 53.9%
H
0.5
3.4
|
L
 -6.2%
H
0.5
10.2
|
L
H
0.5
10.2
|
| Evolus Inc |
|
304.0
|
4.7
|
L
 0.6%
H
4.6
4.8
|
L
 -4.7%
H
4.6
5.0
|
L
 -29.7%
H
4.6
6.8
|
L
 -30.2%
H
4.6
7.8
|
L
 -67%
H
4.6
17.1
|
L
 -52.2%
H
4.6
17.8
|
L
 -30.6%
H
4.6
17.8
|
L
H
2.9
39.5
|
| Erasca Inc |
|
3,253.8
|
10.5
|
L
 1.9%
H
10.2
10.6
|
L
 5.5%
H
9.1
10.7
|
L
 196.9%
H
3.4
10.7
|
L
 327.2%
H
2.1
10.7
|
L
 459.0%
H
1.0
10.7
|
L
 164.7%
H
1.0
10.7
|
L
H
1.0
24.5
|
L
H
1.0
24.5
|
| Esperion Therapeutics Inc |
|
810.4
|
3.4
|
L
 -4.5%
H
3.4
3.6
|
L
 8.0%
H
3.1
3.6
|
L
 -8.1%
H
2.9
4.2
|
L
 19.4%
H
2.4
4.2
|
L
 87.3%
H
0.7
4.2
|
L
 -47.8%
H
0.7
6.7
|
L
 -89.2%
H
0.7
36.9
|
L
 -77.2%
H
0.7
82.7
|
| Eton Pharma Inc |
|
402.5
|
15.0
|
L
 -1.6%
H
15.0
15.4
|
L
 0.1%
H
14.6
15.4
|
L
 -10.6%
H
14.6
17.2
|
L
 -17.8%
H
14.6
20.0
|
L
 -13.3%
H
11.1
23
|
L
 326.4%
H
2.4
23
|
L
 68.3%
H
2.0
23
|
L
H
2.0
23
|
| Exelixis Inc |
|
11,089.1
|
41.4
|
L
 -2.2%
H
40.8
42.5
|
L
 -6.6%
H
40.8
45.0
|
L
 -6.1%
H
40.8
46.3
|
L
 6.2%
H
36
47.2
|
L
 25.6%
H
32.4
49.6
|
L
 137.8%
H
16.2
49.6
|
L
 86.2%
H
14.9
49.6
|
L
 795.2%
H
3.6
49.6
|
| Hyperion DeFi Inc |
|
28.8
|
3.5
|
L
 -3.8%
H
3.3
3.7
|
L
 15.8%
H
2.8
4.0
|
L
 4.5%
H
2.8
4.1
|
L
 -46.7%
H
2.8
6.9
|
L
 26.2%
H
0.0
17.2
|
L
 -98.0%
H
0.0
468
|
L
 -99.3%
H
0.0
617.6
|
L
H
0.0
859.2
|
| EyePoint Pharma Inc |
|
1,119.3
|
13.5
|
L
 -8.3%
H
13.5
14.9
|
L
 -10.9%
H
13.5
15.9
|
L
 -24.4%
H
13.5
18.5
|
L
 10.7%
H
9.7
19.1
|
L
 68.0%
H
3.9
19.1
|
L
 196.5%
H
2.2
31.0
|
L
 20.7%
H
2.2
31.0
|
L
 -60.4%
H
2.2
42.5
|
| Evotec SE (ADR) |
|
1,296.5
|
3.7
|
L
 -3.4%
H
3.6
3.7
|
L
 1.1%
H
3.6
3.8
|
L
 17.0%
H
3.1
3.9
|
L
 -10.1%
H
2.9
4.1
|
L
 -18.7%
H
2.8
4.8
|
L
 -62.9%
H
2.8
13.5
|
L
 -81.5%
H
2.8
26.6
|
L
 103.9%
H
1.6
26.6
|
| Fortress Biotech Inc |
|
96.2
|
3.1
|
L
 -7.7%
H
3.1
3.4
|
L
 -8.8%
H
3.1
3.5
|
L
 -13.4%
H
3.1
4.5
|
L
 20.6%
H
2.4
4.5
|
L
 74.2%
H
1.3
4.5
|
L
 -77.8%
H
1.2
14.3
|
L
 -93.5%
H
1.2
91.5
|
L
 -91.7%
H
1.2
91.5
|
| Fennec Pharma Inc |
|
259.2
|
7.6
|
L
 0.9%
H
7.4
7.6
|
L
 -0.9%
H
7.4
8.0
|
L
 -2.2%
H
7.4
8.1
|
L
 -8.9%
H
7.4
9
|
L
 15.9%
H
4.7
9.9
|
L
 -19.4%
H
4.0
11.9
|
L
 5.4%
H
3.8
11.9
|
L
 268.4%
H
1.4
15.0
|
| Kyntra Bio Inc |
|
31.9
|
7.9
|
L
 -1.6%
H
7.5
8.1
|
L
 -9.8%
H
7.5
9.0
|
L
 -9.4%
H
7.5
9.8
|
L
 -28.6%
H
7.5
11.4
|
L
 -37.4%
H
4.9
22.0
|
L
 -98.5%
H
4.5
642.3
|
L
 -99.3%
H
4.5
1430.2
|
L
 -98.4%
H
4.5
1713.8
|
| Q32 Bio Inc |
|
47.7
|
3.9
|
L
 -3.5%
H
3.9
4.1
|
L
 -1.3%
H
3.7
4.1
|
L
 21.3%
H
3.1
4.2
|
L
 40.6%
H
1.9
6.4
|
L
 19.0%
H
1.3
6.4
|
L
 -85.0%
H
1.3
53.8
|
L
 -98.2%
H
1.3
274.3
|
L
H
1.3
572.4
|
| Amicus Therapeutics Inc |
|
4,482.8
|
14.3
|
L
 0.1%
H
14.3
14.3
|
L
 0.1%
H
14.3
14.3
|
L
 0.3%
H
14.2
14.4
|
L
 60.6%
H
8.6
14.4
|
L
 48.2%
H
5.5
14.4
|
L
 12.1%
H
5.5
14.6
|
L
 -24.4%
H
5.5
21.1
|
L
 136.6%
H
4.4
25.4
|
| Fulcrum Therapeutics Inc |
|
707.9
|
10.7
|
L
 -1.9%
H
10.5
11.1
|
L
 -0.2%
H
10.4
11.3
|
L
 -5.4%
H
9.1
11.8
|
L
 24.8%
H
7.3
15.7
|
L
 156.7%
H
2.3
15.7
|
L
 -16.3%
H
2.3
15.7
|
L
 -3.0%
H
2.3
33.1
|
L
H
2.3
33.1
|
| Generation Bio Co |
|
37.7
|
5.6
|
L
 -0.4%
H
5.6
5.6
|
L
 -1.6%
H
5.5
5.7
|
L
H
5.3
5.8
|
L
 1.6%
H
4.9
5.9
|
L
 -31.2%
H
3
8.5
|
L
 -91.0%
H
3
73.5
|
L
 -97.9%
H
3
418.6
|
L
H
3
557.2
|
| GH Research PLC |
|
971.4
|
15.7
|
L
 -3.6%
H
15.6
16.5
|
L
 -6.4%
H
15.5
16.9
|
L
 25.3%
H
12.4
19
|
L
 24.9%
H
12.0
19
|
L
 61.6%
H
8.0
20.5
|
L
 64.5%
H
5.1
20.5
|
L
H
5.1
30.4
|
L
H
5.1
30.4
|
| Galmed Pharma Ltd |
|
3.9
|
0.7
|
L
 -5.3%
H
0.7
0.7
|
L
 -13.4%
H
0.7
0.9
|
L
 -5.3%
H
0.7
0.9
|
L
 -47.0%
H
0.7
1.5
|
L
 -74.3%
H
0.7
3.5
|
L
 -99.3%
H
0.2
147.4
|
L
 -99.9%
H
0.2
1125
|
L
 -99.9%
H
0.2
4870.8
|
| Galecto Inc |
|
42.0
|
26.2
|
L
 4.5%
H
24
26.8
|
L
 1.9%
H
23.9
27.8
|
L
 17.6%
H
19.4
32
|
L
 257.0%
H
5.0
38.3
|
L
 432.3%
H
2.0
38.3
|
L
 1071.4%
H
0.5
38.3
|
L
 111.8%
H
0.5
38.3
|
L
H
0.5
38.3
|
| GlycoMimetics Inc |
|
618.9
|
9.6
|
L
 -5.4%
H
9.4
11.2
|
L
 -25.1%
H
9.4
12.8
|
L
 -17.3%
H
9.4
14.7
|
L
 -23.3%
H
9.4
16.4
|
L
 -66.7%
H
9.4
37
|
L
 -96.7%
H
9.4
416
|
L
 -97.4%
H
9.4
440
|
L
 -98.0%
H
9.4
2605
|
| Genelux Corp |
|
119.0
|
2.7
|
L
 -2.9%
H
2.6
2.8
|
L
 -7.3%
H
2.6
3.0
|
L
 -38.7%
H
2.5
5.0
|
L
 -66.6%
H
2.5
8.5
|
L
 -32.3%
H
2.0
8.5
|
L
 -54.4%
H
1.6
41.0
|
L
H
1.6
41.0
|
L
H
1.6
41.0
|
| Genprex Inc |
|
6.0
|
2.7
|
L
 8.1%
H
2.5
2.9
|
L
 -6.3%
H
2.1
3.1
|
L
 51.1%
H
1.7
3.6
|
L
 -57.6%
H
1.7
6.3
|
L
 336.1%
H
0.1
13.0
|
L
 76.2%
H
0.1
13.0
|
L
 -40.5%
H
0.1
13.0
|
L
H
0.1
19.5
|
| Gossamer Bio Inc |
|
527.7
|
2.3
|
L
 -5.8%
H
2.3
2.5
|
L
 -15.6%
H
2.3
2.8
|
L
 -26.9%
H
2.3
3.2
|
L
 -5.8%
H
2.2
3.9
|
L
 137.5%
H
0.8
3.9
|
L
 -4.2%
H
0.5
3.9
|
L
 -77.4%
H
0.5
15.2
|
L
H
0.5
27.2
|
| GT Biopharma Inc |
|
17.6
|
0.7
|
L
 -2.9%
H
0.7
0.7
|
L
 -7.0%
H
0.7
0.7
|
L
 -18.5%
H
0.6
0.9
|
L
 4.8%
H
0.5
1.2
|
L
 -68.0%
H
0.5
3.9
|
L
 -20.5%
H
0.2
10.7
|
L
 -91.7%
H
0.2
19.7
|
L
 -100.0%
H
0.2
12240
|
| Genmab (ADR) |
|
20,099.9
|
32.6
|
L
 -2.2%
H
32.2
33.2
|
L
 -3.7%
H
32.2
34.7
|
L
 3.6%
H
30.4
35.4
|
L
 13.8%
H
28.1
35.4
|
L
 64.7%
H
17.2
35.4
|
L
 -15.3%
H
17.2
43
|
L
 -17.8%
H
17.2
49.1
|
L
 161.2%
H
9.2
49.1
|
| Genenta Science SpA (ADR) |
|
23.2
|
1.0
|
L
 -15.4%
H
1.0
1.2
|
L
 -25.6%
H
1.0
1.7
|
L
 -30.3%
H
1.0
1.7
|
L
 -65.5%
H
1.0
2.9
|
L
 -75.3%
H
1.0
10
|
L
 -82.9%
H
1.0
10
|
L
H
1.0
13.1
|
L
H
1.0
13.1
|
| Grifols SA (ADR) - Level III |
|
6,294.7
|
9.3
|
L
 -0.4%
H
9.1
9.3
|
L
 0.3%
H
9.1
9.4
|
L
 0.5%
H
8.6
9.6
|
L
 1.0%
H
7.6
9.9
|
L
 33.9%
H
6.2
11.1
|
L
 2.7%
H
5.3
12.2
|
L
 -47.7%
H
5.3
19.1
|
L
 -36.3%
H
5.3
25.7
|
| Hoth Therapeutics Inc |
|
13.8
|
0.9
|
L
 -3.3%
H
0.9
0.9
|
L
 -16.0%
H
0.9
1.1
|
L
 -11%
H
0.9
1.1
|
L
 -34.6%
H
0.9
1.4
|
L
 -30.5%
H
0.7
2.1
|
L
 -82.1%
H
0.6
5.4
|
L
 -98.3%
H
0.6
87.5
|
L
H
0.6
347
|
| Werewolf Therapeutics Inc |
|
32.0
|
0.7
|
L
 -8.3%
H
0.7
0.8
|
L
 -2.9%
H
0.6
0.8
|
L
 8.2%
H
0.5
0.8
|
L
 -52.9%
H
0.5
1.4
|
L
 -51.1%
H
0.5
2.4
|
L
 -83.9%
H
0.5
8.2
|
L
H
0.5
24.0
|
L
H
0.5
24.0
|
| Harmony Biosciences Holdings Inc |
|
2,103.4
|
36.5
|
L
 -0.9%
H
36.2
37.2
|
L
 -0.8%
H
36.2
38.0
|
L
 -3.0%
H
34.7
39.4
|
L
 26.4%
H
27.7
40.9
|
L
 -7.6%
H
25.5
40.9
|
L
 -23.5%
H
18.6
50.8
|
L
 1.8%
H
18.6
62.1
|
L
H
18.6
62.1
|
| Harrow Health Inc |
|
1,516.3
|
40.9
|
L
 -2.4%
H
40.6
42.4
|
L
 -7.9%
H
40.6
45.1
|
L
 -18.2%
H
40.6
54.9
|
L
 9%
H
32.6
54.9
|
L
 29.2%
H
20.9
54.9
|
L
 179.3%
H
7.6
59.2
|
L
 354.9%
H
5.4
59.2
|
L
 586.9%
H
1.4
59.2
|
| HUTCHMED (China) Ltd (ADR) |
|
2,578.6
|
15
|
L
 -1.6%
H
14.8
15.2
|
L
 -2.0%
H
14.8
15.8
|
L
 13.6%
H
13.2
16.3
|
L
 4.0%
H
13.1
16.3
|
L
 8.6%
H
11.5
19.5
|
L
 -15.2%
H
10.7
21.9
|
L
 -53.0%
H
7.4
43.9
|
L
H
7.4
43.9
|
| ImmunityBio Inc |
|
6,156.0
|
6.3
|
L
 5.8%
H
5.7
6.5
|
L
 -3.1%
H
5.5
6.8
|
L
 215.7%
H
2.0
8.3
|
L
 164.8%
H
2.0
8.3
|
L
 80.1%
H
1.8
8.3
|
L
 65.3%
H
1.2
10.5
|
L
H
1.2
40.8
|
L
H
1.2
40.8
|
| Ideaya Biosciences Inc |
|
2,822.0
|
32.2
|
L
 -2.4%
H
31.6
33.0
|
L
 -7.5%
H
31.6
35.4
|
L
 -6.7%
H
31.6
39.3
|
L
 1.9%
H
28.8
39.3
|
L
 34.8%
H
13.5
39.3
|
L
 94.4%
H
13.3
47.7
|
L
 83.1%
H
8.1
47.7
|
L
H
3.0
47.7
|
| Inhibikase Therapeutics Inc |
|
181.9
|
1.5
|
L
 -4.5%
H
1.5
1.6
|
L
 -13.8%
H
1.5
1.8
|
L
 -23.9%
H
1.5
2.2
|
L
 2.7%
H
1.3
2.2
|
L
 -21.9%
H
1.3
3.3
|
L
 -64.4%
H
0.8
5.6
|
L
 -96.2%
H
0.8
55.0
|
L
H
0.8
70.8
|
| Immix Biopharma Inc |
|
308.7
|
5.8
|
L
 -2.0%
H
5.8
6.2
|
L
 8.4%
H
5.1
6.3
|
L
 10.4%
H
4.2
6.3
|
L
 58.9%
H
2.9
7.7
|
L
 195.9%
H
1.3
7.7
|
L
 140.9%
H
1.3
7.8
|
L
H
0.7
8.7
|
L
H
0.7
8.7
|
| Immuneering Corp (Class A) |
|
299.0
|
4.6
|
L
 -4.9%
H
4.6
5.1
|
L
 -13.6%
H
4.6
5.4
|
L
 -31.2%
H
4.0
8.5
|
L
 -27.8%
H
4.0
8.5
|
L
 138.7%
H
1.1
10.1
|
L
 6.4%
H
1
14.3
|
L
H
1
34.0
|
L
H
1
34.0
|
| Immunic Inc |
|
74.6
|
0.6
|
L
 1.6%
H
0.6
0.6
|
L
 -10.1%
H
0.6
0.7
|
L
 21.6%
H
0.5
0.7
|
L
 -20.5%
H
0.5
0.8
|
L
 -39.2%
H
0.5
1.4
|
L
 -70.5%
H
0.5
3.2
|
L
 -96.3%
H
0.5
28.2
|
L
 -99.8%
H
0.5
390
|
| Incyte |
|
19,646.0
|
100.1
|
L
 -1%
H
99.3
101.3
|
L
 -1.9%
H
98.9
105.1
|
L
 1.2%
H
97.9
112.3
|
L
 8.1%
H
91.2
112.3
|
L
 35.7%
H
53.6
112.3
|
L
 19.6%
H
50.3
112.3
|
L
 11.5%
H
50.3
112.3
|
L
 41.8%
H
50.3
153.2
|
| Indaptus Therapeutics Inc |
|
4.9
|
2.2
|
L
 0.5%
H
2.2
2.3
|
L
 -18.8%
H
2.2
2.7
|
L
 -19.1%
H
2.2
3.7
|
L
 -30.4%
H
1.7
3.7
|
L
 134.0%
H
0.3
13.4
|
L
 29.4%
H
0.3
13.4
|
L
 -86.5%
H
0.3
36.8
|
L
 -99.4%
H
0.3
8800
|
| Indivior PLC |
|
4,423.4
|
35.4
|
L
 1.9%
H
34.3
35.4
|
L
 7.3%
H
33.5
35.5
|
L
 -1.0%
H
31.7
37.7
|
L
 21.5%
H
28.8
38
|
L
 190%
H
7.6
38
|
L
 49.0%
H
7.3
38
|
L
 1921.7%
H
1.6
38
|
L
 1601.0%
H
0.4
38
|
| InMed Pharma Inc |
|
3.1
|
1.1
|
L
 2.8%
H
1.1
1.1
|
L
 -0.9%
H
1.1
1.1
|
L
H
1.0
1.4
|
L
 -40.5%
H
1.0
1.9
|
L
 -66.4%
H
1.0
8.0
|
L
 -96.9%
H
1.0
46.6
|
L
 -99.9%
H
1.0
3210
|
L
 -99.9%
H
1.0
32175
|
| Inovio Pharma Inc |
|
112.0
|
1.6
|
L
 1.2%
H
1.6
1.7
|
L
 8.0%
H
1.5
1.7
|
L
 -7.4%
H
1.5
1.9
|
L
 -30.9%
H
1.5
2.7
|
L
 -22.0%
H
1.3
3.0
|
L
H
0.3
14.8
|
L
 -87.2%
H
0.3
19
|
L
 -75.6%
H
0.3
33.8
|
| Insmed Inc |
|
33,456.2
|
156.9
|
L
 -0.6%
H
154.5
159.5
|
L
 0.4%
H
153.1
165.5
|
L
 -9.9%
H
153.1
186.2
|
L
 -19.2%
H
153.1
212.8
|
L
 105.6%
H
60.4
212.8
|
L
 648.4%
H
16.0
212.8
|
L
 317.3%
H
16.0
212.8
|
L
 1088.4%
H
9.0
212.8
|
| Innoviva Inc |
|
1,495.4
|
20
|
L
 1.3%
H
19.6
20.1
|
L
 2.3%
H
19.4
20.1
|
L
 0.6%
H
19
20.2
|
L
 11.4%
H
17.8
22.8
|
L
 5.8%
H
16.5
22.8
|
L
 60.3%
H
10.6
22.8
|
L
 66.5%
H
10.6
22.8
|
L
 99.6%
H
7.6
22.8
|
| Ionis Pharma Inc |
|
13,390.4
|
82.7
|
L
 -1.4%
H
82.2
83.7
|
L
 3.0%
H
79.2
84.3
|
L
 4.7%
H
74.2
86.2
|
L
 11.5%
H
66.7
86.2
|
L
 148.1%
H
24.0
86.2
|
L
 110.7%
H
24.0
86.2
|
L
 37.6%
H
24.0
86.2
|
L
 112.4%
H
19.6
86.6
|
| Ironwood Pharma Inc (Class A) |
|
795.5
|
4.9
|
L
 0.6%
H
4.7
5
|
L
 -6.5%
H
4.7
5.3
|
L
 46.9%
H
3.3
5.8
|
L
 226%
H
1.6
5.8
|
L
 112.6%
H
0.5
5.8
|
L
 -56.3%
H
0.5
15.7
|
L
 -52.2%
H
0.5
15.7
|
L
 -36.7%
H
0.5
17.7
|
| Iterum Therapeutics PLC |
|
16.5
|
0.3
|
L
H
0.3
0.3
|
L
 -13.9%
H
0.3
0.4
|
L
 6.9%
H
0.3
0.4
|
L
 -52.3%
H
0.3
0.7
|
L
 -80.3%
H
0.3
1.8
|
L
 -76.0%
H
0.3
3.0
|
L
 -98.5%
H
0.3
44.9
|
L
H
0.3
195
|
| I-Mab (ADR) |
|
381.5
|
3.3
|
L
 -10.1%
H
3.3
3.7
|
L
 -14.9%
H
3.3
4.1
|
L
 -16.4%
H
3.3
5.2
|
L
 -27.3%
H
3.3
5.2
|
L
 212.3%
H
0.6
6.8
|
L
 -42.7%
H
0.6
6.8
|
L
 -93.9%
H
0.6
85.4
|
L
H
0.6
85.4
|
| Immuron Ltd (ADR) |
|
7.5
|
0.9
|
L
 2.2%
H
0.9
0.9
|
L
 -5.1%
H
0.9
1.0
|
L
 24%
H
0.7
1.3
|
L
 -54.0%
H
0.7
2
|
L
 -56.9%
H
0.7
2.4
|
L
 -55.7%
H
0.7
6.0
|
L
 -86.6%
H
0.7
9.2
|
L
H
0.7
29.0
|
| Innate Pharma (ADR) |
|
171.5
|
1.8
|
L
 3.4%
H
1.8
1.9
|
L
 2.2%
H
1.7
1.9
|
L
 5.2%
H
1.7
1.9
|
L
 -8.0%
H
1.6
2.4
|
L
 2.2%
H
1.6
2.6
|
L
 -44.4%
H
1.3
3.6
|
L
 -55.3%
H
1.3
12.0
|
L
H
1.3
12.0
|
| Jaguar Health Inc |
|
2.8
|
0.7
|
L
 -1.5%
H
0.7
0.7
|
L
 -10.5%
H
0.7
0.8
|
L
 -31.3%
H
0.6
1.9
|
L
 -65.7%
H
0.6
2.1
|
L
 -24.4%
H
0.4
15.5
|
L
 -99.8%
H
0.4
302.4
|
L
 -100.0%
H
0.4
45090
|
L
 -100.0%
H
0.4
999999
|
| Jazz Pharma PLC |
|
9,995.3
|
164.5
|
L
 0.3%
H
162.7
165.1
|
L
 -2.5%
H
162.7
171.2
|
L
 -3.7%
H
157.0
175.8
|
L
 20.7%
H
128.8
183.0
|
L
 31.5%
H
95.5
183.0
|
L
 7.0%
H
95.5
183.0
|
L
 5.8%
H
95.5
189
|
L
 27.8%
H
86.9
189
|
| Kala Pharma Inc |
|
14.8
|
0.5
|
L
 -1.9%
H
0.5
0.5
|
L
 -11.7%
H
0.5
0.6
|
L
 -7.0%
H
0.5
0.7
|
L
 -30.3%
H
0.5
1.9
|
L
 -94.4%
H
0.5
20.6
|
L
 -97.0%
H
0.5
24
|
L
 -99.9%
H
0.5
498.5
|
L
H
0.5
1337.5
|
| KalVista Pharma Inc |
|
789.0
|
15.6
|
L
 -0.3%
H
15.2
16
|
L
 -2.6%
H
14.6
16.2
|
L
 -0.5%
H
14.2
19
|
L
 42.3%
H
10.4
19
|
L
 78.0%
H
8.7
19
|
L
 99.4%
H
6.3
19
|
L
 2.7%
H
4.1
45
|
L
 -54.1%
H
4.1
45
|
| Kiniksa Pharma Ltd (Class A) |
|
3,328.9
|
43.9
|
L
 -0.1%
H
43.2
44.6
|
L
 4.1%
H
41.5
45
|
L
 7.2%
H
37.0
45
|
L
 17.8%
H
36.6
45
|
L
 120.9%
H
18.1
45
|
L
 215.7%
H
10.3
45
|
L
 123.1%
H
7.4
45
|
L
H
5.0
45
|
| Kiora Pharma Inc |
|
8.8
|
2.4
|
L
 4.4%
H
2.2
2.4
|
L
 13.2%
H
2.0
2.4
|
L
 23.7%
H
1.9
2.4
|
L
 -5.9%
H
1.8
2.6
|
L
 -39.9%
H
1.8
4.2
|
L
 -30.8%
H
0.4
8.5
|
L
 -99.0%
H
0.4
314
|
L
 -99.8%
H
0.4
3060
|
| Karyopharm Therapeutics Inc |
|
119.4
|
6.5
|
L
 -1.7%
H
6.4
6.8
|
L
 -1.1%
H
6.4
7.2
|
L
 -10.8%
H
5.9
9.0
|
L
 9.4%
H
5.0
9.0
|
L
 -34.5%
H
0.6
10.4
|
L
 -85.9%
H
0.6
73.1
|
L
 -97.1%
H
0.6
260.9
|
L
 -93.0%
H
0.6
444.2
|
| Keros Therapeutics Inc |
|
545.6
|
17.9
|
L
 -0.4%
H
17.7
18.3
|
L
 -6.7%
H
17.7
19.1
|
L
 -11.6%
H
17.5
20.5
|
L
 19.2%
H
14.9
22.6
|
L
 53.0%
H
9.1
22.6
|
L
 -69.4%
H
9.1
73
|
L
 -68.6%
H
9.1
76.0
|
L
H
9.1
88.8
|
| Pasithea Therapeutics Corp |
|
19.9
|
0.9
|
L
H
0.8
0.9
|
L
 -4.4%
H
0.8
0.9
|
L
 -25.2%
H
0.8
1.3
|
L
 2.4%
H
0.3
2.1
|
L
 -61.8%
H
0.3
3.9
|
L
 30.3%
H
0.3
9.3
|
L
H
0.3
9.3
|
L
H
0.3
9.3
|
| Kazia Therapeutics Ltd (ADR) |
|
66.4
|
5.9
|
L
 -3.9%
H
5.3
6.4
|
L
 -22.0%
H
5.3
8.2
|
L
 -9.3%
H
5
8.2
|
L
 -23.7%
H
5
17.4
|
L
 -38.3%
H
2.9
17.4
|
L
 -88.4%
H
2.9
84
|
L
 -98.8%
H
2.9
744.5
|
L
 -98.6%
H
2.9
792.5
|
| Lexaria Bioscience Corp |
|
19.4
|
0.8
|
L
 2.6%
H
0.7
0.8
|
L
 -8.2%
H
0.7
0.9
|
L
 44.4%
H
0.5
0.9
|
L
 -20.4%
H
0.5
1.4
|
L
 -57.1%
H
0.5
1.9
|
L
 -75.9%
H
0.5
6.9
|
L
 -83.2%
H
0.5
12.5
|
L
 -77.8%
H
0.5
76.2
|
| Lifecore Biomedical Inc |
|
325.6
|
8.7
|
L
 2.1%
H
8.4
8.8
|
L
 1.3%
H
8.4
9.0
|
L
 7.4%
H
7.3
9.0
|
L
 22.4%
H
6.6
9.0
|
L
 42.5%
H
4.8
9.0
|
L
 35.8%
H
1.5
11.5
|
L
 -18.5%
H
1.5
12.9
|
L
 -27.8%
H
1.5
15.6
|
| Ligand Pharma Inc (Class B) |
|
3,780.9
|
192.1
|
L
 -1.6%
H
189.5
196.4
|
L
 -4.5%
H
189.3
203.5
|
L
 1%
H
175.9
210.3
|
L
 2.7%
H
175.9
212.5
|
L
 61.9%
H
93.6
212.5
|
L
 181.8%
H
49.3
212.5
|
L
 60.6%
H
46.8
212.5
|
L
 197.8%
H
36.9
212.5
|
| Atyr Pharma Inc |
|
86.2
|
0.9
|
L
 3.5%
H
0.8
0.9
|
L
 22.2%
H
0.7
0.9
|
L
 18.9%
H
0.7
0.9
|
L
 -1.1%
H
0.6
0.9
|
L
 -76.5%
H
0.6
7.3
|
L
 -60.9%
H
0.6
7.3
|
L
 -76.0%
H
0.6
13.1
|
L
 -98.8%
H
0.6
90.9
|
| Lipocine Inc |
|
50.0
|
9
|
L
 0.1%
H
8.7
9.2
|
L
 -17.5%
H
8.7
11.1
|
L
 37.0%
H
6.3
12.4
|
L
 246.2%
H
2.5
12.4
|
L
 101.3%
H
2.5
12.4
|
L
 1.8%
H
2.3
12.4
|
L
 -70.1%
H
2.3
38.8
|
L
 -94.2%
H
2.3
215.2
|
| Liquidia Corp |
|
3,687.7
|
42.4
|
L
 -1.6%
H
41.8
43.5
|
L
 4.4%
H
39.7
44.3
|
L
 23.1%
H
29.3
44.3
|
L
 82.7%
H
22.2
44.3
|
L
 194.2%
H
11.3
44.3
|
L
 573.9%
H
5.7
44.3
|
L
 1447.1%
H
2.3
44.3
|
L
H
2.3
44.3
|
| Lisata Therapeutics Inc |
|
40.8
|
4.6
|
L
 -0.2%
H
4.6
4.7
|
L
 12.7%
H
4.1
4.9
|
L
 141.2%
H
1.8
4.9
|
L
 73.4%
H
1.8
4.9
|
L
 78.8%
H
1.8
4.9
|
L
 29.3%
H
1.8
4.9
|
L
 -85.4%
H
1.8
45.8
|
L
 -94.4%
H
1.8
199.5
|
| Lantern Pharma Inc |
|
35.2
|
3.2
|
L
 1.3%
H
3.0
3.3
|
L
 -9.0%
H
3.0
3.5
|
L
 2.9%
H
2.9
3.6
|
L
 -20.7%
H
2.9
4.1
|
L
 -34.5%
H
2.6
5.7
|
L
 -44.5%
H
2.4
12.0
|
L
 -79.0%
H
2.4
23.5
|
L
H
2.4
24.8
|
| Lexicon Pharma Inc |
|
421.6
|
1.2
|
L
 -19.4%
H
1.1
1.3
|
L
 -31.8%
H
1.1
1.7
|
L
 0.9%
H
1.1
1.8
|
L
 -13.4%
H
1.1
1.8
|
L
 41.5%
H
0.3
1.8
|
L
 -46.5%
H
0.3
3.8
|
L
 -85.3%
H
0.3
9.7
|
L
 -88.6%
H
0.3
19.6
|
| Lyra Therapeutics Inc |
|
3.2
|
1.8
|
L
 -12.8%
H
1.8
2.0
|
L
 -13.2%
H
1.6
2.2
|
L
 -44.4%
H
1.6
3.9
|
L
 -67.8%
H
1.6
6.5
|
L
 -80.6%
H
1.6
37.5
|
L
 -98.7%
H
1.6
339.5
|
L
 -99.7%
H
1.6
825
|
L
H
1.6
1100
|
| Legend Biotech Corp (ADR) |
|
3,232.1
|
17.5
|
L
 -1.2%
H
17.0
17.8
|
L
 -7.9%
H
17.0
19.3
|
L
 -18.7%
H
17.0
24.1
|
L
 -45.7%
H
17.0
33.5
|
L
 -53.0%
H
17.0
45.3
|
L
 -65.1%
H
17.0
77.3
|
L
 -30.7%
H
17.0
77.3
|
L
H
17.0
77.3
|
| Mustang Bio Inc |
|
7.0
|
1.0
|
L
 -1.0%
H
1.0
1.0
|
L
 -8.6%
H
1.0
1.1
|
L
 1.1%
H
0.9
1.2
|
L
 -34.3%
H
0.9
1.5
|
L
 -79.5%
H
0.9
7
|
L
 -99.8%
H
0.1
547.5
|
L
 -100.0%
H
0.1
3667.5
|
L
H
0.1
10012.5
|
| Moleculin Biotech Inc |
|
13.2
|
4.3
|
L
 0.2%
H
4.1
4.4
|
L
 -8.3%
H
4.1
4.7
|
L
 29.2%
H
3.2
5.2
|
L
 -62.0%
H
3.1
15.8
|
L
 -88.9%
H
3.1
91.3
|
L
 -99.1%
H
3.1
3318.8
|
L
 -99.8%
H
3.1
3318.8
|
L
H
3.1
21555
|
| Madrigal Pharma Inc |
|
11,112.9
|
489.3
|
L
 -1.1%
H
480.0
497.5
|
L
 1.8%
H
474.9
506.4
|
L
 -16.2%
H
466.0
598.8
|
L
 14.5%
H
399
615
|
L
 44.7%
H
265
615
|
L
 74.0%
H
119.8
615
|
L
 312.0%
H
52.3
615
|
L
 5609.6%
H
5.3
615
|
| MediWound Ltd |
|
232.7
|
18.1
|
L
 3.0%
H
17.0
18.4
|
L
 2.4%
H
17.0
18.7
|
L
 -0.7%
H
16.3
19.7
|
L
 -2.3%
H
16.3
19.7
|
L
 -8.8%
H
14.1
22.5
|
L
 32.0%
H
7.1
24
|
L
 -46.4%
H
7.1
43.5
|
L
 -61.7%
H
7.1
62.3
|
| MEI Pharma Inc |
|
44.5
|
1.2
|
L
 -3.2%
H
1.2
1.3
|
L
 -4.7%
H
1.2
1.3
|
L
 -12.3%
H
1.2
1.7
|
L
 -38.0%
H
1.2
2.3
|
L
 -56.8%
H
1.2
9
|
L
 -79.7%
H
1.2
9
|
L
 -98.1%
H
1.2
91.5
|
L
 -95.2%
H
1.2
102.8
|
| Macrogenics Inc |
|
115.8
|
1.8
|
L
 -5.2%
H
1.7
1.9
|
L
 1.7%
H
1.7
2.0
|
L
 17.3%
H
1.5
2.0
|
L
 14.4%
H
1.3
2.0
|
L
 -39.2%
H
1.0
3.2
|
L
 -67.4%
H
1.0
21.9
|
L
 -91.0%
H
1.0
36.5
|
L
 -90.9%
H
1.0
36.5
|
| Mangoceuticals Inc |
|
5.9
|
0.4
|
L
 -5.3%
H
0.4
0.4
|
L
 -29.4%
H
0.4
0.5
|
L
 -45.5%
H
0.4
1.0
|
L
 -82.4%
H
0.4
2.4
|
L
 -86.8%
H
0.4
6.2
|
L
H
0.1
6.2
|
L
H
0.1
6.2
|
L
H
0.1
6.2
|
| Magenta Therapeutics Inc |
|
-
|
53.4
|
L
 0.1%
H
52.8
57.5
|
L
 2.0%
H
48.9
57.5
|
L
 30.4%
H
35.8
57.5
|
L
 58.2%
H
32.3
57.5
|
L
 171.2%
H
16.6
57.5
|
L
 567.4%
H
7.8
57.5
|
L
 -62.3%
H
5.1
227.2
|
L
H
5.1
336
|
| Mirum Pharma Inc |
|
6,180.8
|
103.2
|
L
 0.3%
H
100.6
103.7
|
L
 9.5%
H
93.2
103.8
|
L
 30.9%
H
73.8
103.8
|
L
 43.0%
H
63.2
103.8
|
L
 113.1%
H
36.9
103.8
|
L
 337.7%
H
20.8
103.8
|
L
 469.6%
H
12.8
103.8
|
L
H
6.5
103.8
|
| Milestone Pharma Inc |
|
162.7
|
1.9
|
L
 1.1%
H
1.9
1.9
|
L
 -3.5%
H
1.9
2.0
|
L
 -2.6%
H
1.9
2.3
|
L
 1.6%
H
1.6
3.1
|
L
 -5.5%
H
0.6
3.1
|
L
 -45.3%
H
0.6
4.5
|
L
 -74.1%
H
0.6
9.9
|
L
H
0.6
28.0
|
| MoonLake Immunotherapeutics (Class A) |
|
1,110.2
|
15.7
|
L
 -3.3%
H
15.6
16.4
|
L
 -1.2%
H
15.2
16.6
|
L
 18.6%
H
11.1
18.8
|
L
 59.7%
H
9.7
18.8
|
L
 -66.7%
H
6.0
62.8
|
L
 31.1%
H
6.0
65.0
|
L
 42.5%
H
4.3
65.0
|
L
H
4.3
65.0
|
| Mannkind Corp |
|
1,774.9
|
5.8
|
L
 -0.2%
H
5.7
5.9
|
L
 5.9%
H
5.4
5.9
|
L
 2.1%
H
5.0
6.5
|
L
 4.1%
H
4.9
6.5
|
L
 -3.2%
H
3.4
6.5
|
L
 12.2%
H
3.2
7.6
|
L
 64.2%
H
2.5
7.6
|
L
 15.8%
H
0.7
11.2
|
| Mind Medicine Inc |
|
1,641.1
|
16.9
|
L
 -2.1%
H
16.6
17.8
|
L
 -3.0%
H
16.4
17.8
|
L
 30.4%
H
12.9
18.1
|
L
 26.1%
H
10.5
18.1
|
L
 136.8%
H
4.7
18.1
|
L
 411.5%
H
2.4
18.1
|
L
 -61.8%
H
2.1
86.6
|
L
H
0.0
154.8
|
| Medicinova Inc |
|
84.5
|
1.7
|
L
 -1.7%
H
1.7
1.8
|
L
 -7.5%
H
1.7
1.9
|
L
 33.3%
H
1.3
1.9
|
L
 44.5%
H
1.2
2.0
|
L
 -16.1%
H
1.1
2.1
|
L
 -28.6%
H
1.1
2.7
|
L
 -70.2%
H
1.1
10.8
|
L
 -57.3%
H
1.1
14.5
|
| TNF Pharma Inc |
|
17.5
|
4.2
|
L
 -6.7%
H
4.1
4.8
|
L
 -26.1%
H
4.1
5.9
|
L
 0.7%
H
3.9
6.3
|
L
 24.0%
H
2.5
8.2
|
L
 -95.3%
H
2.5
96.4
|
L
 -99.9%
H
2.5
8940
|
L
 -99.9%
H
2.5
29850
|
L
 -99.9%
H
2.5
29850
|
| NewAmsterdam Pharma Co NV |
|
3,528.7
|
31.1
|
L
 -1.0%
H
30.5
31.7
|
L
 -6.6%
H
30.5
33.7
|
L
 -10.4%
H
30.2
37.1
|
L
 -19.6%
H
30.2
42
|
L
 43.0%
H
14.1
42
|
L
 75.7%
H
5.6
42
|
L
H
5.6
42
|
L
H
5.6
42
|
| Neurocrine Biosciences Inc |
|
13,566.0
|
136.1
|
L
 -1.4%
H
135.0
138.0
|
L
 -0.1%
H
132.8
138.1
|
L
 -3.5%
H
129.2
142.3
|
L
 -1.4%
H
129.2
160.2
|
L
 -11.2%
H
84.2
160.2
|
L
 25.6%
H
84.2
160.2
|
L
 24.0%
H
71.9
160.2
|
L
 219.8%
H
31.3
160.2
|
| Minerva Neurosciences Inc |
|
175.7
|
4.1
|
L
 -3.3%
H
4.0
4.4
|
L
 2.3%
H
3.9
4.5
|
L
H
3.8
4.9
|
L
 0.5%
H
3.3
4.9
|
L
 70.6%
H
1.2
12.5
|
L
 75%
H
1.2
13.5
|
L
 -84.1%
H
1.2
29.5
|
L
 -90.2%
H
1.2
126.7
|
| Nektar Therapeutics |
|
759.4
|
37.3
|
L
 6.0%
H
33.4
37.7
|
L
 0.6%
H
33.4
38.4
|
L
 -10.9%
H
33.4
45.3
|
L
 -40.6%
H
33.4
66.9
|
L
 192.6%
H
6.5
66.9
|
L
 -4.6%
H
6.2
66.9
|
L
 -87.4%
H
6.2
401.3
|
L
 -81.8%
H
6.2
1670.4
|
| NLS Pharmaceutics Ltd |
|
11.9
|
2.6
|
L
 2.0%
H
2.5
2.7
|
L
 -2.6%
H
2.5
3.1
|
L
 28.1%
H
1.9
3.1
|
L
 -65.9%
H
1.9
7.6
|
L
 -86.9%
H
1.9
33.7
|
L
 -99.5%
H
1.2
704
|
L
 -99.8%
H
1.2
2940
|
L
H
1.2
2940
|
| Nurix Therapeutics Inc |
|
1,699.0
|
16.5
|
L
 -6.1%
H
16.3
17.5
|
L
 -11.0%
H
16.3
19.7
|
L
 -13.1%
H
16.3
20.2
|
L
 29.3%
H
11.7
22.5
|
L
 -17.5%
H
8.2
22.5
|
L
 39.2%
H
4.2
29.6
|
L
 -54.6%
H
4.2
47.8
|
L
H
4.2
52.4
|
| NeuroSense Therapeutics Ltd |
|
27.3
|
0.9
|
L
 -3.2%
H
0.9
1.0
|
L
 -4.2%
H
0.9
1.0
|
L
 29.6%
H
0.7
1.1
|
L
 -11.5%
H
0.7
1.3
|
L
 -13.2%
H
0.7
2.6
|
L
 -41.4%
H
0.4
2.6
|
L
H
0.4
8.2
|
L
H
0.4
8.2
|
| NRX Pharma Inc |
|
62.2
|
2.1
|
L
 -0.9%
H
2.1
2.2
|
L
 -3.2%
H
2.0
2.2
|
L
 -20.2%
H
2
2.8
|
L
 -30.5%
H
2.0
3.4
|
L
 -29.8%
H
1.6
3.8
|
L
 -82.8%
H
1.1
54
|
L
 -99.6%
H
1.1
642
|
L
H
1.1
769.9
|
| Nuvectis Pharma Inc |
|
207.7
|
8.1
|
L
 -4.8%
H
7.9
8.6
|
L
 -5.6%
H
7.9
8.8
|
L
 9.9%
H
7.2
9.4
|
L
 22.1%
H
5.6
9.4
|
L
 20.3%
H
5.6
11.5
|
L
 -13.8%
H
4.4
18.7
|
L
H
3.1
20.9
|
L
H
3.1
20.9
|
| Nextcure Inc |
|
38.0
|
10.9
|
L
 4.1%
H
10.4
11.5
|
L
 -9.0%
H
10.4
12.6
|
L
 -22.4%
H
10.4
14.6
|
L
 -11.4%
H
8.1
15.7
|
L
 13.1%
H
2.8
15.7
|
L
 -45.2%
H
2.8
30.8
|
L
 -92.2%
H
2.8
172.8
|
L
H
2.8
1308
|
| Ocugen Inc |
|
474.6
|
1.5
|
L
 -4.6%
H
1.5
1.5
|
L
 -12.7%
H
1.5
1.7
|
L
 5.8%
H
1.3
2.0
|
L
 -2.0%
H
1.1
2.0
|
L
 88.3%
H
0.5
2.0
|
L
 19.8%
H
0.3
2.1
|
L
 -18.1%
H
0.3
18.8
|
L
 -99.2%
H
0.2
268.2
|
| Oculis Holding AG |
|
1,644.6
|
28.5
|
L
 0.7%
H
27.7
29.0
|
L
 4.8%
H
26.1
29.0
|
L
 42.8%
H
19.6
29.0
|
L
 41.6%
H
18.6
29.0
|
L
 27.3%
H
14
29.0
|
L
 180.3%
H
6.3
29.0
|
L
H
6.3
29.0
|
L
H
6.3
29.0
|
| Ocular Therapeutix Inc |
|
1,947.3
|
9.1
|
L
 -8.1%
H
9.0
10.0
|
L
 -11%
H
9.0
11.1
|
L
 -25.1%
H
9.0
13.0
|
L
 -22.7%
H
9.0
16.4
|
L
 17.5%
H
5.8
16.4
|
L
 135.6%
H
2
16.4
|
L
 -49.6%
H
2
21.5
|
L
 49.3%
H
2
24.3
|
| Opus Genetics Inc |
|
159.3
|
2.3
|
L
 -7.6%
H
2.3
2.5
|
L
 -9.8%
H
2.3
3.1
|
L
 18.5%
H
1.9
3.1
|
L
 17.3%
H
1.7
3.1
|
L
 108.1%
H
0.7
3.1
|
L
 -32.8%
H
0.7
6.6
|
L
 -80.2%
H
0.7
13.8
|
L
 -98.7%
H
0.7
340.8
|
| Olema Pharma Inc |
|
2,061.7
|
25.7
|
L
 -1.3%
H
25.1
26.2
|
L
 1.9%
H
24.3
26.6
|
L
 2.6%
H
23.9
29.5
|
L
 192.9%
H
7.8
36.3
|
L
 306.3%
H
2.9
36.3
|
L
 437.0%
H
2.9
36.3
|
L
 -39.4%
H
2
54.9
|
L
H
2
60.3
|
| Omeros Corp |
|
828.8
|
11.7
|
L
 -2.2%
H
11.6
12.2
|
L
 -2.0%
H
11.5
12.7
|
L
 -31.1%
H
11.5
17.6
|
L
 55.5%
H
6.2
17.7
|
L
 32.2%
H
3.0
17.7
|
L
 311.6%
H
0.9
17.7
|
L
 -39.9%
H
0.9
23.9
|
L
 8.3%
H
0.9
27.1
|
| ORIC Pharma Inc |
|
999.2
|
10.3
|
L
 -4.7%
H
10.2
10.9
|
L
 -14.4%
H
10.2
12.6
|
L
 27.0%
H
7.8
12.7
|
L
 -23.1%
H
7.8
13.6
|
L
 -4.7%
H
3.9
14.9
|
L
 82.2%
H
3.9
16.7
|
L
 -65.0%
H
2.4
37
|
L
H
2.4
40.8
|
| Oramed Pharma Inc |
|
134.1
|
3.4
|
L
 -1.5%
H
3.3
3.4
|
L
 -0.6%
H
3.3
3.6
|
L
 19.9%
H
2.8
3.7
|
L
 40.4%
H
2.1
3.7
|
L
 53.2%
H
1.8
3.7
|
L
 69.3%
H
1.7
5.3
|
L
 -53.6%
H
1.7
31.5
|
L
 -47.3%
H
1.7
31.5
|
| Outlook Therapeutics Inc |
|
32.3
|
0.4
|
L
 -4.4%
H
0.4
0.5
|
L
 -12%
H
0.4
0.5
|
L
 -76.3%
H
0.4
1.8
|
L
 -64.5%
H
0.4
2.5
|
L
 -78.2%
H
0.4
3.0
|
L
 -99.9%
H
0.4
812
|
L
 -99.9%
H
0.4
1704
|
L
H
0.4
17568
|
| Ovid Therapeutics Inc |
|
111.1
|
1.6
|
L
 0.7%
H
1.5
1.6
|
L
 -7.7%
H
1.5
1.8
|
L
 -4.3%
H
1.5
1.9
|
L
 13.9%
H
1.2
1.9
|
L
 122.9%
H
0.2
2.0
|
L
 -37.6%
H
0.2
4.1
|
L
 -44.5%
H
0.2
4.8
|
L
H
0.2
15.9
|
| Phibro Animal Health Corp (Class A) |
|
1,627.4
|
40.2
|
L
 0.7%
H
39.2
40.4
|
L
 2.9%
H
38.5
40.7
|
L
 7.0%
H
36.5
42.8
|
L
 -4.1%
H
36.1
46.4
|
L
 82.7%
H
16.2
46.4
|
L
 165.9%
H
9.4
46.4
|
L
 93.6%
H
9.4
46.4
|
L
 19.7%
H
9.4
54.6
|
| Palisade Bio Inc |
|
222.3
|
1.5
|
L
 -7.5%
H
1.5
1.6
|
L
 -22.0%
H
1.5
1.9
|
L
 -36.9%
H
1.5
2.6
|
L
 -23.2%
H
1.5
2.6
|
L
 4.2%
H
0.5
2.6
|
L
 -95.6%
H
0.4
54.8
|
L
 -100.0%
H
0.4
12015
|
L
 -100.0%
H
0.4
1275300
|
| Puma biotech Inc |
|
326.5
|
6.5
|
L
 0.8%
H
6.3
6.5
|
L
 0.9%
H
6.3
6.6
|
L
 7.8%
H
5.6
7.2
|
L
 18.7%
H
4.6
7.2
|
L
 113.2%
H
2.6
7.2
|
L
 51.8%
H
2.1
7.7
|
L
 -44.8%
H
1.6
14.1
|
L
 -84.5%
H
1.6
136.9
|
| Pacira BioSciences Inc |
|
844.2
|
20.5
|
L
 2.2%
H
19.9
20.6
|
L
 -0.6%
H
19.7
20.9
|
L
 -21.2%
H
18.8
26.8
|
L
 -3.4%
H
18.8
27.2
|
L
 -21.7%
H
18.8
27.6
|
L
 -47.2%
H
11.2
48.6
|
L
 -68.9%
H
11.2
82.2
|
L
 -65.4%
H
11.2
82.2
|
| Processa Pharma Inc |
|
6.8
|
3
|
L
 -4.5%
H
2.9
3.1
|
L
 -8.0%
H
2.9
3.4
|
L
 2.4%
H
2.8
3.8
|
L
 -66.2%
H
2.8
10.3
|
L
 -81.7%
H
2.8
19.6
|
L
 -99.3%
H
2.8
635
|
L
 -99.9%
H
2.8
7120
|
L
 -100.0%
H
2.8
17937.5
|
| PDS biotech Corp |
|
45.4
|
0.8
|
L
 -4.6%
H
0.8
0.9
|
L
 -12.6%
H
0.8
1.1
|
L
 3.8%
H
0.8
1.2
|
L
 -12.6%
H
0.7
1.2
|
L
 -50%
H
0.7
2.2
|
L
 -90.1%
H
0.7
10.3
|
L
 -72.8%
H
0.7
17.9
|
L
 -99.6%
H
0.6
355.4
|
| Phathom Pharma Inc |
|
1,066.4
|
13.7
|
L
 1.0%
H
13.1
13.8
|
L
 1.3%
H
13.1
14.3
|
L
 -19.2%
H
13.1
18.1
|
L
 2.7%
H
12.3
18.3
|
L
 115.6%
H
2.2
18.3
|
L
 14.0%
H
2.2
19.7
|
L
 -64.5%
H
2.2
50.8
|
L
H
2.2
64.5
|
| Pharvaris NV |
|
1,757.2
|
27.1
|
L
 -2.7%
H
26.8
27.9
|
L
 -3.3%
H
26.7
28.2
|
L
 3.1%
H
23.6
28.5
|
L
 21.6%
H
21.0
29.8
|
L
 52.6%
H
11.5
29.8
|
L
 197.3%
H
6.0
33
|
L
H
1.8
42.9
|
L
H
1.8
42.9
|
| Praxis Precision Medicines Inc |
|
8,710.0
|
314
|
L
 -0.1%
H
309.1
319.1
|
L
 0.7%
H
289.5
323.4
|
L
 5.7%
H
266.9
326.9
|
L
 56.2%
H
154.5
326.9
|
L
 312.1%
H
26.7
326.9
|
L
 336.1%
H
11.9
326.9
|
L
 -58.9%
H
11.9
828.9
|
L
H
11.9
914.3
|
| PainReform Ltd |
|
2.7
|
0.7
|
L
 -2.8%
H
0.7
0.7
|
L
 -11.5%
H
0.7
0.8
|
L
 3.0%
H
0.6
1.6
|
L
 -42.5%
H
0.6
1.6
|
L
 -79.2%
H
0.6
5.5
|
L
 -97.7%
H
0.2
158.5
|
L
 -99.7%
H
0.2
470.4
|
L
H
0.2
471
|
| ProQR Therapeutics NV |
|
170.7
|
1.6
|
L
 1.3%
H
1.6
1.7
|
L
 -7.4%
H
1.6
1.8
|
L
 -19%
H
1.6
2.3
|
L
 -40.4%
H
1.6
2.8
|
L
 -24.7%
H
1.1
3.1
|
L
 -40.2%
H
1.1
4.6
|
L
 -65.1%
H
0.5
9.5
|
L
 -69.3%
H
0.5
24
|
| Plus Therapeutics Inc |
|
41.0
|
0.2
|
L
 -4.2%
H
0.2
0.2
|
L
 -14.8%
H
0.2
0.3
|
L
 -57.4%
H
0.2
0.6
|
L
 -56.6%
H
0.2
0.8
|
L
 -80.8%
H
0.2
2.3
|
L
 -96.6%
H
0.2
6.8
|
L
 -99.4%
H
0.2
81.3
|
L
 -100.0%
H
0.2
40500
|
| PTC Therapeutics Inc |
|
6,064.2
|
75.5
|
L
 -1.2%
H
74.7
77.6
|
L
 0.4%
H
73.8
78.4
|
L
 -0.9%
H
69.8
80.2
|
L
 10.9%
H
66.1
87.5
|
L
 63.7%
H
36.0
87.5
|
L
 66.0%
H
17.5
87.5
|
L
 30.6%
H
17.5
87.5
|
L
 217.1%
H
4.0
87.5
|
| Pulmatrix Inc |
|
9.4
|
2.6
|
L
 -1.9%
H
2.6
2.7
|
L
 -3.4%
H
2.5
2.8
|
L
 17.9%
H
2.2
3.0
|
L
 -48.0%
H
2.2
5.0
|
L
 -66.5%
H
2.2
10.4
|
L
 -36.9%
H
1.6
10.4
|
L
 -90.9%
H
1.6
60.8
|
L
 -99.5%
H
1.6
1396
|
| Polypid Ltd |
|
76.2
|
4.6
|
L
 -2.8%
H
4.5
4.8
|
L
 -4.2%
H
4.5
4.9
|
L
 4.6%
H
4.1
5.1
|
L
 19.3%
H
3.5
5.1
|
L
 53.2%
H
2.3
5.1
|
L
 -80.5%
H
2.3
25.7
|
L
 -98.4%
H
2.3
495
|
L
H
2.3
583.5
|
| Pyxis Oncology Inc |
|
90.3
|
1.5
|
L
 -7.1%
H
1.4
1.6
|
L
 -11.0%
H
1.4
1.7
|
L
 33.0%
H
1.1
2.2
|
L
 -57.6%
H
1.0
5.6
|
L
 -10.5%
H
0.8
5.6
|
L
 -7.1%
H
0.8
6.9
|
L
H
0.8
19
|
L
H
0.8
19
|
| Pharming Grp N.V. (ADR) |
|
1,426.1
|
20.5
|
L
 -1.1%
H
20.2
21.0
|
L
 3.9%
H
19.9
21.3
|
L
 21.8%
H
16.6
21.3
|
L
 55.8%
H
12.7
21.3
|
L
 132.6%
H
7.5
21.3
|
L
 46.2%
H
6.7
21.3
|
L
 43.1%
H
6.1
21.3
|
L
H
6.1
22.0
|
| Purple Biotech Ltd (ADR) |
|
5.4
|
0.6
|
L
 -3.2%
H
0.6
0.6
|
L
 -9.1%
H
0.6
0.7
|
L
 -7.7%
H
0.6
0.7
|
L
 -36.2%
H
0.6
0.9
|
L
 -81.6%
H
0.5
3.5
|
L
 -98.1%
H
0.5
47.4
|
L
 -99.2%
H
0.5
145
|
L
 -99.9%
H
0.5
1390
|
| Qilian Intl Holding Grp ltd (Class A) |
|
708.2
|
3.5
|
L
 -1.4%
H
3.4
3.8
|
L
 -5.1%
H
3.3
4.0
|
L
 -8.3%
H
3.3
4.3
|
L
 -61.3%
H
3.3
10.1
|
L
 -64.0%
H
3.3
17.2
|
L
 -59.2%
H
1.8
17.2
|
L
 -89.8%
H
1.8
42.4
|
L
H
1
110
|
| Quoin Pharma Ltd (ADR) |
|
11.7
|
7.2
|
L
 -13.0%
H
7
8.4
|
L
 -24.8%
H
7
10.3
|
L
 -46.5%
H
7
14.5
|
L
 -36.8%
H
7
23.5
|
L
 -96.4%
H
5.1
329
|
L
 -99.9%
H
5.1
23688
|
L
 -100.0%
H
5.1
3003840
|
L
H
5.1
3003840
|
| RAPT Therapeutics Inc |
|
1,670.4
|
57.7
|
L
 0.1%
H
57.6
57.8
|
L
 0.1%
H
57.6
57.8
|
L
 72.8%
H
29.8
57.8
|
L
 94.2%
H
26.5
57.8
|
L
 532.5%
H
5.7
57.8
|
L
 -73.3%
H
5.7
251.6
|
L
 -63.8%
H
5.7
346.1
|
L
H
5.7
409.7
|
| Ultragenyx Pharmaceutical Inc |
|
2,322.2
|
24.1
|
L
 -0.8%
H
23.3
24.6
|
L
 -0.6%
H
23.3
25
|
L
 5.7%
H
21.9
25.1
|
L
 -31.6%
H
18.4
39.9
|
L
 -44.5%
H
18.4
46.5
|
L
 -44.0%
H
18.4
60.4
|
L
 -82.6%
H
18.4
175
|
L
 -57.1%
H
18.4
179.7
|
| Regeneron Pharma |
|
77,926.0
|
741.5
|
L
 -1.1%
H
735.6
774.4
|
L
 -1.6%
H
735.6
776.3
|
L
 -4.2%
H
718.4
821.1
|
L
 13.4%
H
625.1
821.1
|
L
 8.6%
H
476.5
821.1
|
L
 0.7%
H
476.5
1211.2
|
L
 47.2%
H
441
1211.2
|
L
 76.5%
H
271.4
1211.2
|
| Regencell Bioscience Holdings Ltd |
|
12,357.3
|
25.0
|
L
 -10.4%
H
24.3
27.7
|
L
 -20.4%
H
24.3
34.0
|
L
 9.1%
H
20.5
69
|
L
 52.8%
H
10.3
69
|
L
 24890%
H
0.1
83.6
|
L
 3232%
H
0.1
83.6
|
L
H
0.1
83.6
|
L
H
0.1
83.6
|
| Repligen Corp |
|
8,408.1
|
149.4
|
L
 -4.5%
H
148.8
157.4
|
L
 -8.0%
H
148.8
166.8
|
L
 -10.3%
H
148.8
175.8
|
L
 3.3%
H
139.4
175.8
|
L
 -10.8%
H
103.0
175.8
|
L
 -17.1%
H
103.0
211.1
|
L
 -25.3%
H
103.0
327.3
|
L
 574.4%
H
20.1
327.3
|
| Regenxbio Inc |
|
565.0
|
11.2
|
L
 -3.8%
H
11.0
11.6
|
L
 -19.1%
H
9.5
14.2
|
L
 -20.8%
H
9.5
16.2
|
L
 -13.0%
H
9.5
16.2
|
L
 41.3%
H
5.0
16.2
|
L
 -50.3%
H
5.0
28.8
|
L
 -73.0%
H
5.0
49.5
|
L
 -19.7%
H
5.0
85.1
|
| Rigel Pharma |
|
632.8
|
34.9
|
L
 -0.9%
H
33.9
35.4
|
L
 -5.7%
H
33.9
37.8
|
L
 -18.6%
H
33.9
49.1
|
L
 10.3%
H
28.1
52.2
|
L
 54.3%
H
15.5
52.2
|
L
 2012.7%
H
0.7
52.2
|
L
 857.7%
H
0.6
52.2
|
L
 1167.6%
H
0.6
52.2
|
| Relmada Therapeutics Inc |
|
260.3
|
3.6
|
L
 -9.2%
H
3.5
3.9
|
L
 -9.0%
H
3.5
4.2
|
L
 -21.6%
H
3.5
5.0
|
L
 53.0%
H
2.2
5.1
|
L
 914.3%
H
0.2
5.1
|
L
 -12.6%
H
0.2
7.2
|
L
 -89.1%
H
0.2
40
|
L
 -36.2%
H
0.2
54
|
| RenovoRx Inc |
|
38.1
|
1.0
|
L
 8.3%
H
0.9
1.1
|
L
 4%
H
0.9
1.1
|
L
 18.2%
H
0.8
1.3
|
L
 2.0%
H
0.7
1.3
|
L
 -23.0%
H
0.7
1.5
|
L
 -60.2%
H
0.6
5.7
|
L
H
0.6
16.7
|
L
H
0.6
16.7
|
| Roivant Sciences Ltd |
|
15,036.5
|
21.6
|
L
 -1.8%
H
21.5
22.0
|
L
 -4.3%
H
21.5
23.1
|
L
 -0.1%
H
20.8
23.9
|
L
 10.4%
H
19.3
23.9
|
L
 90.2%
H
8.7
23.9
|
L
 161.7%
H
6.6
23.9
|
L
 109.5%
H
2.5
23.9
|
L
H
2.5
23.9
|
| Royalty Pharma PLC (Class A) |
|
17,807.7
|
41.7
|
L
 2.0%
H
40.9
41.7
|
L
 3.2%
H
40.2
41.7
|
L
 6.9%
H
38.3
41.7
|
L
 12.8%
H
36.0
41.7
|
L
 31.9%
H
29.7
41.7
|
L
 7.9%
H
24.1
41.7
|
L
 -11.3%
H
24.1
50.2
|
L
H
24.1
56.5
|
| Reviva Pharma Holdings Inc |
|
33.9
|
0.3
|
L
 -3.3%
H
0.3
0.3
|
L
 -12.1%
H
0.3
0.3
|
L
 3.6%
H
0.3
0.4
|
L
 -51.7%
H
0.3
0.8
|
L
 -84.2%
H
0.3
2.2
|
L
 -93.3%
H
0.3
9.3
|
L
 -96.4%
H
0.3
9.5
|
L
H
0.3
15.1
|
| Rezolute Inc |
|
309.7
|
3.3
|
L
 2.8%
H
3.2
3.4
|
L
 -5.1%
H
3.2
3.6
|
L
 52.5%
H
1.9
3.7
|
L
 -66.0%
H
1.1
11.5
|
L
 -35.9%
H
1.1
11.5
|
L
 39.7%
H
0.7
11.5
|
L
 -79.1%
H
0.7
17.5
|
L
 -94.9%
H
0.7
100
|
| Redhill Biopharma (ADR) |
|
6.2
|
1.2
|
L
 -3.9%
H
1.2
1.3
|
L
 -10.3%
H
1.2
1.4
|
L
 18.5%
H
0.9
1.4
|
L
 -9.6%
H
0.9
1.6
|
L
 -79.4%
H
0.9
6.3
|
L
 -99.4%
H
0.9
276
|
L
 -100.0%
H
0.9
11520
|
L
 -100.0%
H
0.9
16540
|
| Sunshine Biopharma Inc |
|
6.0
|
1.2
|
L
 -1.6%
H
1.2
1.3
|
L
 -0.8%
H
1.2
1.4
|
L
 -0.8%
H
1.2
1.4
|
L
 -30.3%
H
1.2
1.9
|
L
 -56.0%
H
1.2
3.9
|
L
 -98.9%
H
0.1
140
|
L
 -99.9%
H
0.1
6280
|
L
 -100.0%
H
0.1
224000
|
| Scilex Holding Co |
|
59.9
|
8.5
|
L
 -2.0%
H
8.3
9.0
|
L
 -22.5%
H
8.2
11.1
|
L
 -30.7%
H
8.2
14.1
|
L
 -52.8%
H
8.2
27
|
L
 1836.4%
H
0.2
34.3
|
L
 -2.0%
H
0.2
34.3
|
L
H
0.2
34.3
|
L
H
0.2
34.3
|
| Scynexis Inc |
|
29.8
|
0.7
|
L
 -4.1%
H
0.7
0.7
|
L
 -13.4%
H
0.7
0.9
|
L
 16.4%
H
0.6
0.9
|
L
 2.9%
H
0.6
0.9
|
L
 -35.5%
H
0.6
1.3
|
L
 -59.4%
H
0.6
3.9
|
L
 -90.5%
H
0.6
10.3
|
L
 -98.4%
H
0.6
55.5
|
| Shuttle Pharma Holdings Inc |
|
3.9
|
2.0
|
L
 -7.8%
H
2.0
2.2
|
L
 -19.2%
H
1.9
2.5
|
L
 16.1%
H
1.3
4.4
|
L
 -33.8%
H
1.3
4.4
|
L
 -89.7%
H
1.3
20.0
|
L
 -99.5%
H
1.3
550
|
L
H
1.3
25252
|
L
H
1.3
25252
|
| SIGA Tech Inc |
|
479.8
|
6.7
|
L
 -1.6%
H
6.6
6.8
|
L
 0.9%
H
6.6
6.9
|
L
 8.6%
H
6.1
6.9
|
L
 -19.4%
H
5.7
8.5
|
L
 8.8%
H
5.0
9.6
|
L
 -8.2%
H
4.2
12.8
|
L
 3.7%
H
4.2
27.0
|
L
 1356.5%
H
0.4
27.0
|
| SILO Pharma Inc |
|
4.5
|
0.3
|
L
 3.0%
H
0.3
0.4
|
L
 -8.1%
H
0.3
0.4
|
L
 -2.9%
H
0.3
0.4
|
L
 -38.2%
H
0.3
0.6
|
L
 -81.4%
H
0.3
1.9
|
L
 -86.9%
H
0.3
4.5
|
L
 -98.1%
H
0.3
496
|
L
 -99.3%
H
0.3
496
|
| Sol-Gel Tech Ltd |
|
178.9
|
64.2
|
L
 5.5%
H
58.5
65
|
L
 9.9%
H
55.5
65.2
|
L
 51.3%
H
41.7
75
|
L
 73.6%
H
28.8
75
|
L
 8240.3%
H
0.4
75
|
L
 1202.6%
H
0.3
75
|
L
 560.0%
H
0.3
75
|
L
H
0.3
75
|
| Soleno Therapeutics Inc |
|
2,071.1
|
38.6
|
L
 -4.9%
H
38.0
40.8
|
L
 -9.0%
H
38.0
43.3
|
L
 -16.7%
H
38.0
50.9
|
L
 -44.3%
H
38.0
70.0
|
L
 -22.6%
H
38.0
90.3
|
L
 1292.1%
H
1.8
90.3
|
L
 31.2%
H
0.9
90.3
|
L
 -61.6%
H
0.9
131.3
|
| SELLAS Life Sciences Grp Inc |
|
642.0
|
3.8
|
L
 -3.1%
H
3.7
3.9
|
L
 -11.5%
H
3.7
4.7
|
L
 13.9%
H
3.2
5.2
|
L
 97.4%
H
1.4
5.2
|
L
 183.5%
H
1.0
5.2
|
L
 16%
H
0.5
5.2
|
L
 -38.2%
H
0.5
15.1
|
L
 -100.0%
H
0.5
74703
|
| Soligenix Inc |
|
12.6
|
1.3
|
L
 -4.6%
H
1.2
1.3
|
L
 -9.4%
H
1.2
1.4
|
L
 -6.0%
H
1.2
1.5
|
L
 -17.2%
H
1.2
1.7
|
L
 -45.9%
H
1.1
6.2
|
L
 -98.8%
H
1.1
115.2
|
L
 -99.7%
H
1.1
595.2
|
L
 -99.9%
H
1.1
2292.1
|
| Sonoma Pharma Inc |
|
5.6
|
3.3
|
L
 -1.8%
H
3.3
3.3
|
L
 -4.4%
H
3.3
3.5
|
L
 -9.4%
H
3.2
3.9
|
L
 -17.0%
H
3.1
4.0
|
L
 23.3%
H
1.8
6.9
|
L
 94.1%
H
0.1
6.9
|
L
 -59.9%
H
0.1
13.4
|
L
 -94.2%
H
0.1
74.2
|
| Synaptogenix Inc |
|
31.8
|
4.3
|
L
 -7.6%
H
4.2
4.6
|
L
 -6.8%
H
4.2
5.3
|
L
 12.7%
H
3.5
5.9
|
L
 -43.2%
H
3.5
9
|
L
 27.5%
H
1.8
12.0
|
L
 302.8%
H
0.1
12.0
|
L
 -18.5%
H
0.1
14.5
|
L
H
0.1
14.5
|
| SciSparc Ltd |
|
3.3
|
0.8
|
L
 -2.5%
H
0.7
0.8
|
L
 -23.8%
H
0.7
1
|
L
 -43.0%
H
0.7
1.6
|
L
 -76.3%
H
0.7
3.4
|
L
 -91.7%
H
0.7
12.1
|
L
 -99.8%
H
0.7
726.2
|
L
H
0.7
4641
|
L
H
0.7
4641
|
| ARS Pharma Inc |
|
987.5
|
10.0
|
L
 -2.3%
H
9.8
10.3
|
L
 -2.2%
H
9.8
10.8
|
L
 -14.2%
H
9.8
13.2
|
L
 15.9%
H
6.7
13.2
|
L
 -30.1%
H
6.7
18.9
|
L
 57.6%
H
2.6
18.9
|
L
 -77.3%
H
2.6
63.4
|
L
H
2.6
63.4
|
| SeqLL Inc |
|
173.5
|
3.5
|
L
 2.1%
H
3.3
3.5
|
L
 -10.4%
H
3.1
4.0
|
L
 160.2%
H
1.3
4
|
L
 35.7%
H
1.2
4
|
L
 33.1%
H
1.2
5.3
|
L
 620.8%
H
0.3
35.4
|
L
H
0.2
35.4
|
L
H
0.2
35.4
|
| Sarepta Therapeutics Inc |
|
2,131.4
|
20.3
|
L
 -4.2%
H
20.2
21.3
|
L
 -3.7%
H
20.2
24.7
|
L
 -5.4%
H
20.1
24.7
|
L
 -12.5%
H
15.1
24.7
|
L
 -82.2%
H
10.4
120.1
|
L
 -83.2%
H
10.4
173.3
|
L
 -77.2%
H
10.4
173.3
|
L
 71.2%
H
8
181.8
|
| Sutro Biopharma Inc |
|
127.4
|
15.0
|
L
 0.2%
H
13.9
15.1
|
L
 -0.7%
H
13.9
16.9
|
L
 28.1%
H
10.2
17.3
|
L
 28.9%
H
7.2
17.3
|
L
 -23.3%
H
5.2
21.3
|
L
 -79.2%
H
5.2
74.1
|
L
 -93.3%
H
5.2
283
|
L
H
5.2
283
|
| Supernus Pharma Inc |
|
2,761.5
|
48.2
|
L
 -1.8%
H
48.0
49.1
|
L
 -0.2%
H
48.0
50.1
|
L
 -3.5%
H
47.8
52.5
|
L
 -14.8%
H
43.1
57.4
|
L
 24.5%
H
29.2
57.7
|
L
 17.3%
H
22
57.7
|
L
 63.9%
H
22
57.7
|
L
 324.7%
H
9.5
61.3
|
| Savara Inc |
|
1,098.7
|
5.4
|
L
 -3.2%
H
5.4
5.6
|
L
 -10.3%
H
5.4
6
|
L
 -11.6%
H
5.4
6.5
|
L
 25.6%
H
3.9
7
|
L
 92.9%
H
1.9
7
|
L
 104.5%
H
1.6
7
|
L
 252.9%
H
1.0
7
|
L
 -80.7%
H
0.7
49.6
|
| China SXT Pharma Inc |
|
3.8
|
0.0
|
L
 -40%
H
0.0
0.0
|
L
 -66.7%
H
0.0
0.1
|
L
 -97.9%
H
0.0
7.0
|
L
 -97.8%
H
0.0
7.0
|
L
 -92.7%
H
0.0
7.0
|
L
 -99.8%
H
0.0
16
|
L
 -100.0%
H
0.0
128
|
L
H
0.0
2335
|
| Sanofi (ADR) |
|
114,090.8
|
47.0
|
L
 1.8%
H
46.6
47.2
|
L
 -0.3%
H
45.7
47.9
|
L
 -3.5%
H
45.3
49.3
|
L
 -7.7%
H
45.3
52.7
|
L
 -13.1%
H
44.6
60.1
|
L
 -3.2%
H
42.6
60.1
|
L
 -0.4%
H
36.9
60.1
|
L
 13.0%
H
36.8
60.1
|
| Protara Therapeutics Inc |
|
379.4
|
7.1
|
L
 1.1%
H
6.9
7.3
|
L
 14.4%
H
6
7.4
|
L
 34.9%
H
4.7
7.4
|
L
 37.7%
H
4.1
7.8
|
L
 57.3%
H
2.8
7.8
|
L
 125.5%
H
1.0
10.5
|
L
 -60.6%
H
1.0
23.0
|
L
 -98.1%
H
1.0
465.2
|
| Tarsus Pharma Inc |
|
2,739.7
|
64.5
|
L
 -1.8%
H
62.7
66.4
|
L
 -5.6%
H
62.7
69.5
|
L
 -21.6%
H
62.7
83.9
|
L
 -6.4%
H
62.7
85.3
|
L
 24.7%
H
38.5
85.3
|
L
 316.9%
H
11.3
85.3
|
L
 71.2%
H
10.8
85.3
|
L
H
10.8
85.3
|
| Theravance Biopharma Inc |
|
959.7
|
18.9
|
L
 -1.3%
H
18.8
19.3
|
L
 -6.4%
H
18.8
20.2
|
L
 0.2%
H
17.6
21.0
|
L
 32.5%
H
14.1
21.0
|
L
 95.9%
H
7.9
21.0
|
L
 78.3%
H
7.4
21.0
|
L
 1.6%
H
6.1
22.7
|
L
 15.3%
H
6.1
43.4
|
| Tenax Therapeutics Inc |
|
78.1
|
12.5
|
L
 -6.4%
H
12.4
13.8
|
L
 -14.9%
H
12.4
15.6
|
L
 4.3%
H
10.9
18.4
|
L
 67.5%
H
6.5
18.4
|
L
 108.5%
H
4.6
18.4
|
L
 -92.8%
H
2.8
344
|
L
 -99.7%
H
2.8
4864
|
L
 -100.0%
H
2.8
94080
|
| TG Therapeutics Inc |
|
4,672.3
|
29.4
|
L
 -1.9%
H
29.3
30.3
|
L
 -5.7%
H
29.3
31.3
|
L
 -1.1%
H
26.9
33.2
|
L
 -13.5%
H
26.9
36.7
|
L
 -11.8%
H
25.3
46.5
|
L
 103.0%
H
6.5
46.5
|
L
 -39.0%
H
3.5
56.5
|
L
 260.2%
H
3.3
56.7
|
| Alpha Teknova Inc |
|
129.5
|
2.4
|
L
 -14.8%
H
2.3
2.8
|
L
 -27.1%
H
2.3
3.5
|
L
 -36.5%
H
2.3
4.3
|
L
 -52.2%
H
2.3
5.3
|
L
 -74.5%
H
2.3
10
|
L
 -58.6%
H
1.2
10.4
|
L
H
1.2
30.9
|
L
H
1.2
30.9
|
| Tiziana Life Sciences Ltd |
|
192.1
|
1.5
|
L
 -5.6%
H
1.5
1.6
|
L
 -7.4%
H
1.5
1.8
|
L
 -2.0%
H
1.3
1.8
|
L
 -17.9%
H
1.3
2.0
|
L
 118.8%
H
0.6
2.6
|
L
 139.7%
H
0.4
2.6
|
L
 -59.0%
H
0.4
5.0
|
L
H
0.4
12.2
|
| Tonix Pharma Holding Corp |
|
220.5
|
17.2
|
L
 -5.4%
H
17.0
18.6
|
L
 -5.9%
H
17.0
18.8
|
L
 9.0%
H
14.9
20.0
|
L
 -4.5%
H
13.7
20.6
|
L
 -54.0%
H
0.2
70.0
|
L
 -99.9%
H
0.2
26600
|
L
 -100.0%
H
0.2
1356800
|
L
 -100.0%
H
0.2
3187200000
|
| Tenaya Therapeutics Inc |
|
168.9
|
0.8
|
L
 -1.3%
H
0.8
0.8
|
L
 6.9%
H
0.7
0.8
|
L
 11.4%
H
0.7
0.8
|
L
 -38.1%
H
0.7
1.6
|
L
 -26.4%
H
0.4
2.4
|
L
 -76.9%
H
0.4
8.1
|
L
H
0.4
32
|
L
H
0.4
32
|
| Tempest Therapeutics Inc |
|
13.4
|
2.7
|
L
 -3.2%
H
2.7
2.8
|
L
 -8.7%
H
2.6
3
|
L
 -4.2%
H
2.4
3.2
|
L
 -74.1%
H
2.4
10.7
|
L
 189.4%
H
0.4
12.2
|
L
 36%
H
0.2
12.2
|
L
 -90.8%
H
0.2
41.6
|
L
 -99.8%
H
0.2
2623.5
|
| Travere Therapeutics Inc |
|
2,781.7
|
31.1
|
L
 -2.8%
H
30.7
32.0
|
L
 5.6%
H
29
32.1
|
L
 -17.5%
H
22.6
40.8
|
L
 4.9%
H
22.6
42.1
|
L
 47.7%
H
12.9
42.1
|
L
 45.1%
H
5.1
42.1
|
L
 23.1%
H
5.1
42.1
|
L
 107.7%
H
5.1
42.1
|
| TherapeuticsMD Inc |
|
25.0
|
2.2
|
L
 -6.1%
H
2.1
2.4
|
L
 -17.2%
H
2.1
3.0
|
L
 31.7%
H
1.6
3.0
|
L
 74.2%
H
1.1
3.0
|
L
 100%
H
0.7
3.0
|
L
 -58.6%
H
0.7
5.5
|
L
 -97.4%
H
0.7
137.5
|
L
 -99.4%
H
0.7
464.5
|
| Universe Pharma INC |
|
-
|
4.4
|
L
 6.3%
H
4.2
4.6
|
L
 8.6%
H
4
4.6
|
L
 11.6%
H
3.8
4.6
|
L
 -6.0%
H
3.3
7.2
|
L
 952.4%
H
0.1
11
|
L
 -65.2%
H
0.1
64.8
|
L
H
0.1
179.9
|
L
H
0.1
179.9
|
| United Therapeutics Corp |
|
20,214.6
|
469.5
|
L
 0.4%
H
462.0
470.9
|
L
 0.1%
H
462.0
479.4
|
L
 -5.4%
H
455.6
512.7
|
L
 3.5%
H
430.0
520.0
|
L
 33.3%
H
267.0
520.0
|
L
 81.5%
H
204.4
520.0
|
L
 186.6%
H
155.7
520.0
|
L
 281.1%
H
74.3
520.0
|
| Vericel Corp |
|
1,819.7
|
36.0
|
L
 -1.4%
H
35.8
37.2
|
L
 -4.9%
H
35.6
38.3
|
L
 -2.0%
H
35.3
41.7
|
L
 4.2%
H
33.8
43
|
L
 -39.3%
H
29.2
63
|
L
 33.1%
H
27.0
63
|
L
 -12.8%
H
17.3
68.9
|
L
 1605.2%
H
1.8
68.9
|
| Veru Inc |
|
40.6
|
2.5
|
L
 -3.1%
H
2.5
2.7
|
L
 -9.6%
H
2.5
2.8
|
L
 16.6%
H
2.1
2.8
|
L
 -16.0%
H
2.1
3.0
|
L
 -56.5%
H
2.1
7.4
|
L
 -95.5%
H
2.1
63.4
|
L
 -97.1%
H
2.1
245.7
|
L
 -80.4%
H
2.1
245.7
|
| Dogwood Therapeutics Inc |
|
89.5
|
2.8
|
L
 -3.8%
H
2.8
3.0
|
L
 -6.4%
H
2.8
3.5
|
L
 -32.6%
H
2.6
4.3
|
L
 -58.1%
H
2.6
7.0
|
L
 -78.1%
H
2.6
15
|
L
 771.9%
H
0.1
29.3
|
L
 -58.9%
H
0.1
29.3
|
L
H
0.1
29.3
|
| Viking Therapeutics Inc |
|
3,282.6
|
29.0
|
L
 -4.0%
H
29.0
30.6
|
L
 -9.9%
H
29.0
32.7
|
L
 -17.8%
H
29.0
36.2
|
L
 -23.9%
H
29.0
43.2
|
L
 -13.8%
H
18.9
43.2
|
L
 244.5%
H
8.3
99.4
|
L
 297.3%
H
2.0
99.4
|
L
 1296.2%
H
0.9
99.4
|
| Vanda Pharma Inc |
|
445.6
|
7.5
|
L
 -3.1%
H
7.4
7.8
|
L
 -5.9%
H
7.4
8.1
|
L
 7.3%
H
7.1
9.6
|
L
 74.5%
H
4.3
9.6
|
L
 64.6%
H
3.8
9.6
|
L
 -0.8%
H
3.3
9.6
|
L
 -47.4%
H
3.3
21.9
|
L
 -11.6%
H
3.3
33.4
|
| Verrica Pharma Inc |
|
112.4
|
7.0
|
L
 -2.5%
H
7
7.3
|
L
 -5.3%
H
7
7.5
|
L
 -15.3%
H
7
9.0
|
L
 99.2%
H
3.3
9.8
|
L
 876.4%
H
0.4
9.8
|
L
 53.5%
H
0.4
11.4
|
L
 -40.2%
H
0.4
18.4
|
L
H
0.4
23.3
|
| Viridian Therapeutics Inc |
|
3,147.1
|
33
|
L
 -1.7%
H
31.3
33.5
|
L
 0.2%
H
31.3
34.2
|
L
 6.4%
H
29.0
34.3
|
L
 39.5%
H
22.1
34.3
|
L
 64.3%
H
9.9
34.3
|
L
 -6.8%
H
9.9
38
|
L
 85.2%
H
9.5
39
|
L
 -73.3%
H
4.7
270
|
| Vertex Pharma |
|
119,222.5
|
469.9
|
L
 -1.2%
H
468
475.7
|
L
 0.3%
H
468
485
|
L
 3.6%
H
429
487.5
|
L
 11.9%
H
403.2
487.5
|
L
 7.2%
H
362.5
519.7
|
L
 46.9%
H
283.6
519.9
|
L
 105.1%
H
176.4
519.9
|
L
 417.8%
H
71.5
519.9
|
| Viatris |
|
15,076.7
|
13.1
|
L
 0.2%
H
12.9
13.1
|
L
 -0.9%
H
12.9
13.4
|
L
 4.4%
H
12.2
13.5
|
L
 26.4%
H
9.9
13.5
|
L
 14.6%
H
6.9
13.5
|
L
 9.6%
H
6.9
13.6
|
L
 -23.0%
H
6.9
18.7
|
L
 -75.2%
H
6.9
53.2
|
| vTv Therapeutics Inc (Class A) |
|
139.4
|
35.4
|
L
 3.7%
H
32.2
36.2
|
L
 3.8%
H
32.2
36.2
|
L
 -9.2%
H
31.8
44
|
L
 68.1%
H
20.0
44
|
L
 141.5%
H
14
44
|
L
 3791.2%
H
0.4
44
|
L
 1635.8%
H
0.4
44
|
L
 388.4%
H
0.4
44
|
| VYNE Therapeutics Inc |
|
19.0
|
0.6
|
L
H
0.6
0.6
|
L
 -1.7%
H
0.6
0.6
|
L
 1.8%
H
0.6
0.6
|
L
 54.1%
H
0.3
0.8
|
L
 -75.9%
H
0.3
2.9
|
L
 -87.1%
H
0.3
8.7
|
L
 -99.6%
H
0.3
237.6
|
L
H
0.3
2869.9
|
| Vaccitech PLC (ADR) |
|
28.1
|
0.7
|
L
 1.4%
H
0.7
0.7
|
L
 1.4%
H
0.7
0.7
|
L
 7.4%
H
0.7
0.8
|
L
 -43.4%
H
0.7
1.4
|
L
 -22.3%
H
0.7
2.9
|
L
 -74.4%
H
0.7
5.1
|
L
H
0.7
18.0
|
L
H
0.7
18.0
|
| Xenetic Biosciences Inc |
|
5.1
|
2.2
|
L
 -4.7%
H
2.2
2.4
|
L
 -16.2%
H
2.2
2.7
|
L
 6.7%
H
2.1
2.8
|
L
 -32.5%
H
1.9
3.5
|
L
 -46.6%
H
1.9
13.9
|
L
 -66.6%
H
1.9
13.9
|
L
 -90.6%
H
1.9
56.8
|
L
 -99.8%
H
1.9
1782
|
| Xenon Pharma Inc |
|
3,169.0
|
41.0
|
L
 -1.8%
H
40.4
42.1
|
L
 -1.8%
H
40.4
43.7
|
L
 -7.1%
H
39.3
46.4
|
L
 -3.9%
H
37.2
46.6
|
L
 1.3%
H
26.7
46.6
|
L
 7.9%
H
26.7
51.0
|
L
 185.8%
H
14.3
51.0
|
L
 520.4%
H
2.1
51.0
|
| Xilio Therapeutics Inc |
|
40.5
|
0.6
|
L
 -1.6%
H
0.6
0.6
|
L
 -4.8%
H
0.6
0.6
|
L
 -7.7%
H
0.6
0.7
|
L
 -25%
H
0.6
0.9
|
L
 -14.3%
H
0.6
1.7
|
L
 -84.9%
H
0.5
4.1
|
L
H
0.5
28.0
|
L
H
0.5
28.0
|
| XOMA Corp |
|
317.8
|
25.7
|
L
 2.8%
H
24.3
25.8
|
L
 -3.9%
H
24.1
26.7
|
L
 -2.0%
H
24.1
30.8
|
L
 -22.8%
H
24.1
34.9
|
L
 -2.3%
H
18.4
39.9
|
L
 20.8%
H
13.5
39.9
|
L
 -29.2%
H
13.5
44.5
|
L
 27.0%
H
4.0
46.3
|
| XORTX Therapeutics Inc |
|
3.5
|
0.5
|
L
 2.0%
H
0.5
0.6
|
L
 -12.3%
H
0.5
0.6
|
L
 -10.7%
H
0.5
0.6
|
L
 -20.6%
H
0.5
0.7
|
L
 -47.4%
H
0.5
1.4
|
L
 -15.3%
H
0.3
7
|
L
 -81.6%
H
0.3
8.2
|
L
H
0.3
8.2
|
| Zevra Therapeutics Inc |
|
506.7
|
9
|
L
 1.6%
H
8.6
9.0
|
L
 0.3%
H
8.5
9.2
|
L
 2.2%
H
8.1
9.6
|
L
 -11.2%
H
8.0
10.6
|
L
 12.2%
H
6.2
13.2
|
L
 67.0%
H
3.9
13.2
|
L
 49.3%
H
3.9
18.2
|
L
 -96.3%
H
1.9
316
|
| Zymeworks BC Inc |
|
1,698.5
|
22.5
|
L
 0.7%
H
22
22.8
|
L
 -3.1%
H
22
23.3
|
L
 -15.1%
H
22
27.1
|
L
 17.8%
H
16
28.5
|
L
 52.9%
H
9.0
28.5
|
L
 136.2%
H
6.0
28.5
|
L
 -33.4%
H
4.1
43.3
|
L
H
4.1
59.0
|
| Sagimet Biosciences Inc (Class A) |
|
184.4
|
5.7
|
L
 5.8%
H
5.1
5.8
|
L
 -7.7%
H
5.0
6.2
|
L
 -3.1%
H
5.0
6.6
|
L
 -30.3%
H
5.0
8.8
|
L
 39.7%
H
1.7
11.4
|
L
 -25.6%
H
1.7
20.7
|
L
 -25.6%
H
1.7
20.7
|
L
 -25.6%
H
1.7
20.7
|
| CervoMed Inc |
|
47.7
|
5.2
|
L
 -0.4%
H
4.9
5.3
|
L
 -18.0%
H
4.9
6.4
|
L
 -35.5%
H
4.9
8.2
|
L
 -27.6%
H
4.9
10
|
L
 128.9%
H
1.9
16.9
|
L
 -45.0%
H
1.8
26.4
|
L
 -94.0%
H
1.8
138.8
|
L
 -100.0%
H
1.8
17437.5
|
| Dianthus Therapeutics Inc |
|
2,307.7
|
53.4
|
L
 0.1%
H
52.8
57.5
|
L
 2.0%
H
48.9
57.5
|
L
 30.4%
H
35.8
57.5
|
L
 58.2%
H
32.3
57.5
|
L
 145.3%
H
13.4
57.5
|
L
 6925%
H
6.6
57.5
|
L
 6925%
H
6.6
57.5
|
L
 6925%
H
6.6
57.5
|
| Neumora Therapeutics Inc |
|
338.2
|
2.0
|
L
 -2.9%
H
2.0
2.0
|
L
 -3.4%
H
2.0
2.2
|
L
 12.4%
H
1.5
2.6
|
L
 -32.1%
H
1.5
3.3
|
L
 3.7%
H
0.6
3.3
|
L
H
0.6
21
|
L
H
0.6
21
|
L
H
0.6
21
|
| Agape ATP Corp |
|
3.5
|
0.1
|
L
 -12.5%
H
0.1
0.1
|
L
 -12.5%
H
0.1
0.1
|
L
 -36.4%
H
0.1
0.2
|
L
 -94.1%
H
0.1
1.5
|
L
 -95.1%
H
0.1
2.6
|
L
 -95.5%
H
0.1
3.5
|
L
 -95.5%
H
0.1
3.5
|
L
 -95.5%
H
0.1
3.5
|
| Barinthus Biotherapeutics PLC. (ADR) |
|
29.8
|
0.7
|
L
 1.4%
H
0.7
0.7
|
L
 1.4%
H
0.7
0.7
|
L
 7.4%
H
0.7
0.8
|
L
 -43.4%
H
0.7
1.4
|
L
 -27%
H
0.6
2.9
|
L
 -79.9%
H
0.6
5.1
|
L
 -79.9%
H
0.6
5.1
|
L
 -79.9%
H
0.6
5.1
|
| Onconetix Inc |
|
2.2
|
1.4
|
L
 -4.7%
H
1.3
1.5
|
L
 -10.1%
H
1.3
1.7
|
L
 -0.7%
H
1.3
2.3
|
L
 -62.5%
H
1.3
3.7
|
L
 153.6%
H
0.1
5.9
|
L
 -97.2%
H
0.1
78
|
L
 -22.0%
H
0.1
3636
|
L
 -22.0%
H
0.1
3636
|
| Talphera Inc |
|
44.7
|
1.0
|
L
 -1.0%
H
0.9
1.0
|
L
 -4%
H
0.9
1.0
|
L
 -11.1%
H
0.9
1.3
|
L
 -22.6%
H
0.9
1.6
|
L
 37.1%
H
0.4
1.6
|
L
H
0.4
1.6
|
L
H
0.4
1.6
|
L
H
0.4
1.6
|
| ArriVent BioPharma Inc |
|
928.4
|
22.5
|
L
 0.0%
H
22.2
23.4
|
L
 -3.1%
H
22.2
24.3
|
L
 8.5%
H
18.2
26
|
L
 21.8%
H
17
26
|
L
 -22.7%
H
15.5
29.7
|
L
H
14.4
36.2
|
L
H
14.4
36.2
|
L
H
14.4
36.2
|
| Skye Bioscience Inc |
|
32.4
|
1.0
|
L
 5.2%
H
0.9
1.0
|
L
H
0.9
1.1
|
L
 38.4%
H
0.7
1.2
|
L
 -31.3%
H
0.7
1.6
|
L
 -73.1%
H
0.7
5.8
|
L
H
0.7
7.2
|
L
H
0.7
7.2
|
L
H
0.7
7.2
|
| Actuate Therapeutics Inc |
|
109.5
|
4.7
|
L
 -0.6%
H
4.6
4.9
|
L
 -11.3%
H
4.6
5.8
|
L
 -21.8%
H
4.6
7.1
|
L
 -28.4%
H
4.6
7.9
|
L
 -46.7%
H
4.6
12.0
|
L
H
4.6
12.0
|
L
H
4.6
12.0
|
L
H
4.6
12.0
|
| Bicara Therapeutics Inc |
|
920.3
|
16.8
|
L
 -0.7%
H
16.2
17.2
|
L
 0.4%
H
16.1
17.4
|
L
 4.2%
H
15.6
18.4
|
L
 2.1%
H
13.7
19.7
|
L
 30.1%
H
7.8
19.7
|
L
H
7.8
28.1
|
L
H
7.8
28.1
|
L
H
7.8
28.1
|
| Gelteq Ltd |
|
10.4
|
1.0
|
L
 -4.0%
H
1.0
1.0
|
L
 -7.6%
H
1.0
1.1
|
L
 21.3%
H
0.7
1.4
|
L
 -17.1%
H
0.7
1.4
|
L
 -60.9%
H
0.7
4.1
|
L
H
0.7
5.5
|
L
H
0.7
5.5
|
L
H
0.7
5.5
|
| Septerna Inc |
|
1,045.0
|
23.3
|
L
 -1.9%
H
23.2
23.9
|
L
 -9.4%
H
23.2
26.6
|
L
 -16.0%
H
23.2
29
|
L
 8.6%
H
17.6
30.5
|
L
 31.8%
H
4.2
30.5
|
L
H
4.2
30.5
|
L
H
4.2
30.5
|
L
H
4.2
30.5
|
| Alpha Cognition Inc |
|
105.2
|
4.8
|
L
 -6.6%
H
4.8
5.4
|
L
 -18.7%
H
4.8
6.0
|
L
 -26.7%
H
4.8
6.8
|
L
 -21.7%
H
4.8
6.9
|
L
 -19.3%
H
3.8
11.5
|
L
H
3.8
11.5
|
L
H
3.8
11.5
|
L
H
3.8
11.5
|
| Atlantic Intl Corp |
|
245.8
|
3.5
|
L
 2.1%
H
3.3
3.5
|
L
 -10.4%
H
3.1
4.0
|
L
 160.2%
H
1.3
4
|
L
 35.7%
H
1.2
4
|
L
 33.1%
H
1.2
5.3
|
L
 33.1%
H
1.2
5.3
|
L
 33.1%
H
1.2
5.3
|
L
 33.1%
H
1.2
5.3
|
| BeiGene Ltd (ADR) |
|
37,665.7
|
340.4
|
L
 -2.8%
H
339.2
350.0
|
L
 0.3%
H
334.4
353
|
L
 11.7%
H
302.6
353.1
|
L
 10.4%
H
299.5
385.2
|
L
 50.0%
H
196.5
385.2
|
L
 84.3%
H
172.7
385.2
|
L
 84.3%
H
172.7
385.2
|
L
 84.3%
H
172.7
385.2
|
| Jupiter Neurosciences Inc |
|
18.2
|
0.5
|
L
 -11.7%
H
0.5
0.6
|
L
 -40.5%
H
0.5
0.9
|
L
 -50.9%
H
0.5
1.1
|
L
 -61.6%
H
0.5
1.5
|
L
 -8.6%
H
0.5
3.3
|
L
 -8.6%
H
0.5
3.3
|
L
 -8.6%
H
0.5
3.3
|
L
 -8.6%
H
0.5
3.3
|
| Ascentage Pharma Grp Intl (ADR) |
|
2,247.9
|
24.2
|
L
 -3.3%
H
24.2
24.8
|
L
 -8.7%
H
24.2
26.3
|
L
 -7.3%
H
24.2
28.8
|
L
 -26.1%
H
24.2
34.5
|
L
 37.4%
H
17.1
48.5
|
L
 39.1%
H
17
48.5
|
L
 39.1%
H
17
48.5
|
L
 39.1%
H
17
48.5
|
| Maze Therapeutics Inc |
|
2,097.0
|
43.6
|
L
 -3.2%
H
43.4
45.7
|
L
 -1.6%
H
42.2
47.0
|
L
 8.8%
H
37.4
47.4
|
L
 31.2%
H
27.0
47.4
|
L
H
6.7
47.4
|
L
H
6.7
47.4
|
L
H
6.7
47.4
|
L
H
6.7
47.4
|
| Aardvark Therapeutics Inc |
|
282.8
|
13.0
|
L
 -2.7%
H
12.4
13.8
|
L
 -13.5%
H
12.4
15.4
|
L
 -1.7%
H
12.4
16.6
|
L
 24.2%
H
8.8
16.6
|
L
H
4.9
19.6
|
L
H
4.9
19.6
|
L
H
4.9
19.6
|
L
H
4.9
19.6
|
| Cuprina Holdings (Cayman) Ltd (Class A) |
|
9.0
|
0.4
|
L
 -10.6%
H
0.4
0.5
|
L
H
0.4
0.5
|
L
 10.5%
H
0.4
0.5
|
L
 -52.3%
H
0.4
1.0
|
L
H
0.4
9.5
|
L
H
0.4
9.5
|
L
H
0.4
9.5
|
L
H
0.4
9.5
|
| Jyong Biotech Ltd |
|
175.2
|
2.4
|
L
 -7.8%
H
2.4
2.7
|
L
 -22.1%
H
2.4
3.2
|
L
 -44.1%
H
2.4
5.4
|
L
 -94.8%
H
2.4
45.4
|
L
 -76.7%
H
2.4
67
|
L
 -76.7%
H
2.4
67
|
L
 -76.7%
H
2.4
67
|
L
 -76.7%
H
2.4
67
|
| Black Titan Corp |
|
17.2
|
1.9
|
L
 -1.1%
H
1.8
2
|
L
 -17.8%
H
1.8
2.4
|
L
 13.2%
H
1.5
3.3
|
L
 -49.9%
H
1.5
10.1
|
L
 -92.1%
H
1.5
23.5
|
L
 -92.1%
H
1.5
23.5
|
L
 -92.1%
H
1.5
23.5
|
L
 -92.1%
H
1.5
23.5
|
| MapLight Therapeutics Inc |
|
802.6
|
17.7
|
L
 -4.8%
H
17.5
18.6
|
L
 -1.6%
H
17.1
19.3
|
L
 -1.3%
H
15.6
20.5
|
L
 -3.7%
H
12.2
21.6
|
L
 -3.5%
H
12.2
21.6
|
L
 -3.5%
H
12.2
21.6
|
L
 -3.5%
H
12.2
21.6
|
L
 -3.5%
H
12.2
21.6
|
| NovaBridge Biosciences ADR |
|
381.6
|
3.3
|
L
 -10.1%
H
3.3
3.7
|
L
 -14.9%
H
3.3
4.1
|
L
 -16.4%
H
3.3
5.2
|
L
 -27.3%
H
3.3
5.2
|
L
 -27.3%
H
3.3
5.2
|
L
 -27.3%
H
3.3
5.2
|
L
 -27.3%
H
3.3
5.2
|
L
 -27.3%
H
3.3
5.2
|
| Evommune Inc |
|
570.6
|
18.1
|
L
 -16.4%
H
18
23
|
L
 -4.1%
H
17.7
23.3
|
L
 3.3%
H
14.8
23.3
|
L
 -10.5%
H
13.9
24.0
|
L
 -10.5%
H
13.9
24.0
|
L
 -10.5%
H
13.9
24.0
|
L
 -10.5%
H
13.9
24.0
|
L
 -10.5%
H
13.9
24.0
|
| Aktis Oncology Inc |
|
-
|
20.3
|
L
 3.1%
H
19.2
20.4
|
L
 -6.5%
H
19.2
22.4
|
L
 -9.6%
H
18.5
24.5
|
L
 -9.6%
H
18.5
24.5
|
L
 -9.6%
H
18.5
24.5
|
L
 -9.6%
H
18.5
24.5
|
L
 -9.6%
H
18.5
24.5
|
L
 -9.6%
H
18.5
24.5
|
| Helus Pharma Inc |
|
-
|
6.6
|
L
 -2.2%
H
6.5
6.9
|
L
 -12.2%
H
6.5
7.6
|
L
 -12.1%
H
6.5
8.2
|
L
 -12.1%
H
6.5
8.2
|
L
 -12.1%
H
6.5
8.2
|
L
 -12.1%
H
6.5
8.2
|
L
 -12.1%
H
6.5
8.2
|
L
 -12.1%
H
6.5
8.2
|
| NervGen Pharma Corp |
|
317.6
|
4.0
|
L
 -3.8%
H
3.9
4.3
|
L
 -20.9%
H
3.9
5.1
|
L
 -30.3%
H
3.9
5.9
|
L
 -30.3%
H
3.9
5.9
|
L
 -30.3%
H
3.9
5.9
|
L
 -30.3%
H
3.9
5.9
|
L
 -30.3%
H
3.9
5.9
|
L
 -30.3%
H
3.9
5.9
|